AB 170: Newborn screening: genetic diseases: blood samples collected.
- Session Year: 2015-2016
- House: Assembly
- Latest Version Date: 2015-07-08
Existing law requires the State Department of Public Health to establish a program for the development, provision, and evaluation of genetic disease testing, and the program is required to provide genetic screening and followup services for persons who have the screening. The program includes statewide screening of newborn children through the collection of blood samples, unless the parent or guardian objects on the grounds of religious beliefs or practices.
This bill would require the department to provide information about the testing program, and to obtain a form signed by the parent or guardian acknowledging receiving information regarding the storage, retention, and use of the newborn childs blood sample for medical research. The bill would authorize a parent or guardian of a minor child, and the newborn child, once he or she is at least 18 years of age, to request that the department destroy the blood sample, not use it for research purposes, or both, and the bill would require the department to comply with the request. The bill would require the department, if the individual making a request to destroy the blood sample or to not use it for research purposes provides his or her e-mail address, to send an e-mail to the individual acknowledging that the department received the request. The bill would also require the department to prepare and provide informational materials regarding the same information about the newborn childs blood sample collected pursuant to the program, information on storage, retention, and use of the blood sample for medical research, and the right of specified persons to request that the blood sample be destroyed or not used for research purposes in a separate, single-page format. The bill would also require the department to prepare and provide a standard informational acceptance form, that includes, among other things, a brief, plain language explanation of, and the purpose for, the newborn child screening test and retention of newborn child blood samples. The bill would require the informational acceptance form to be provided to, and signed by, the parent or guardian when either version of the informational materials is provided. The bill would require specified persons to distribute the informational material and the informational acceptance form, including requiring the local registrar of births to provide a copy of the informational material and a copy of the standard informational acceptance form to each person registering the birth of a newborn that occurred outside of a perinatal licensed health facility, as specified. The bill would also require the local registrar to notify the local health officer and the department of each of these registrations by the local registrar. By imposing additional duties on local registrars of births, this bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that, if the Commission on State Mandates determines that the bill contains costs mandated by the state, reimbursement for those costs shall be made pursuant to these statutory provisions.
Existing law requires the State Department of Public Health to establish a program for the development, provision, and evaluation of genetic disease testing, and the program is required to provide genetic screening and followup services for persons who have the screening. The program includes statewide screening of newborn children through the collection of blood samples, unless the parent or guardian objects on the grounds of religious beliefs or practices.
This bill would require the department to provide information about the testing program, and to obtain a form signed by the parent or guardian acknowledging receiving information regarding the storage, retention, and use of the newborn childs blood sample for medical research. The bill would authorize a parent or guardian of a minor child, and the newborn child, once he or she is at least 18 years of age, to request that the department destroy the blood sample, not use it for research purposes, or both, and the bill would require the department to comply with the request. The bill would also require the department to prepare and provide informational materials regarding the same information about the newborn childs blood sample collected pursuant to the program, information on storage, retention, and use of the blood sample for medical research, and the right of specified persons to request that the blood sample be destroyed or not used for research purposes in a separate, single-page format. The bill would also require the department to prepare and provide a standard informational acceptance form, that includes, among other things, a brief, plain language explanation of, and the purpose for, the newborn child screening test and retention of newborn child blood samples. The bill would require the informational acceptance form to be provided to, and signed by, the parent or guardian when either version of the informational materials is provided. The bill would require specified persons to distribute the informational material and the informational acceptance form, including requiring the local registrar of births to provide a copy of the informational material and a copy of the standard informational acceptance form to each person registering the birth of a newborn that occurred outside of a perinatal licensed health facility, as specified. The bill would also require the local registrar to notify the local health officer and the department of each of these registrations by the local registrar. By imposing additional duties on local registrars of births, this bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that, if the Commission on State Mandates determines that the bill contains costs mandated by the state, reimbursement for those costs shall be made pursuant to these statutory provisions.
Existing law requires the State Department of Public Health to establish a program for the development, provision, and evaluation of genetic disease testing, and the program is required to provide genetic screening and followup services for persons who have the screening. The program includes statewide screening of newborn children through the collection of blood samples, unless the parent or guardian objects on the grounds of religious beliefs or practices.
This bill would provide that the program for testing the blood sample of a newborn child and the authority to store, retain, or use the sample for medical research would not apply to a parent or guardian of the newborn child who objects to the testing program. The bill would require the department to provide information about the testing program, and to obtain a form signed by the parent or guardian acknowledging receiving information regarding the storage, retention, and use of the newborn childs blood sample for medical research. The bill would authorize a parent or guardian of a minor child, and the newborn child, once he or she is at least 18 years of age, to request that the department destroy the blood sample, not use it for research purposes, or both, and the bill would require the department to comply with the request. The bill would also require the department to prepare and provide informational materials regarding the same information about the newborn childs blood sample collected pursuant to the program, information on storage, retention, and use of the blood sample for medical research, and the right of specified persons to request that the blood sample be destroyed or not used for research purposes in a separate, single-page format. The bill would also require the department to prepare and provide a standard informational acceptance form, that includes, among other things, a brief, plain language explanation of, and the purpose for, the newborn child screening test and retention of newborn child blood samples. The bill would require the informational acceptance form to be provided to, and signed by, the parent or guardian when either version of the informational materials is provided. The bill would require specified persons to distribute the informational material and the informational acceptance form, including requiring the local registrar of births to provide a copy of the informational material and a copy of the standard informational acceptance form to each person registering the birth of a newborn that occurred outside of a perinatal licensed health facility, as specified. The bill would also require the local registrar to notify the local health officer and the department of each of these registrations by the local registrar. By imposing additional duties on local registrars of births, this bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that, if the Commission on State Mandates determines that the bill contains costs mandated by the state, reimbursement for those costs shall be made pursuant to these statutory provisions.
Existing law requires the State Department of Public Health to establish a program for the development, provision, and evaluation of genetic disease testing, and the program is required to provide genetic screening and followup services for persons who have the screening. The program includes statewide screening of newborn children through the collection of blood samples, unless the parent or guardian objects on the grounds of religious beliefs or practices.
This bill would instead prohibit the department from both testing a newborn child unless the parent or guardian is fully informed, as specified, and from storing, retaining, or using for medical research a blood sample collected unless the parent or guardian provides informed consent, as specified. provide that the program for testing the blood sample of a newborn child and the authority to store, retain, or use the sample for medical research would not apply to a parent or guardian of the newborn child who objects to the testing program. The bill would require the department to provide information about the testing program, and to obtain a form signed by the parent or guardian acknowledging receiving information regarding the storage, retention, and use of the newborn childs blood sample for medical research. The bill would authorize a parent or guardian of a minor child child, and the newborn child, once he or she is at least 18 years of age, to request that the department destroy or the blood sample, not use it for research purposes, or both, the blood sample, and the bill would require the department would be required to do so to comply with the request. The bill would also require the department to prepare and provide informational materials, to be distributed as specified, regarding the same information about the newborn child childs blood sample collected pursuant to the program that includes, but is not limited to, program, information on storage, retention, and use of the blood sample, for medical research, and the right of specified persons to request that the blood sample be destroyed or not used for research purposes, or both. in a separate, single-page format. The bill would also require the department to prepare and provide a standard informed consent informational acceptance form, to be distributed as specified, that includes, among other things, an explanation of the newborn child screening test and a space for the parent or legal guardian of the newborn child to indicate his or her consent to the storage, retention, and use of the blood sample for medical research. a brief, plain language explanation of, and the purpose for, the newborn child screening test and retention of newborn child blood samples. The bill would require the informational acceptance form to be provided to, and signed by, the parent or guardian when either version of the informational materials is provided. The bill would require specified persons to distribute the informational material and the informational acceptance form, including requiring the local registrar of births to provide a copy of the informational material and a copy of the standard informational acceptance form to each person registering the birth of a newborn that occurred outside of a perinatal licensed health facility, as specified. The bill would also require the local registrar to notify the local health officer and the department of each of these registrations by the local registrar. By imposing additional duties on local registrars of births, this bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that, if the Commission on State Mandates determines that the bill contains costs mandated by the state, reimbursement for those costs shall be made pursuant to these statutory provisions.
Existing law requires the State Department of Public Health to establish a program for the development, provision, and evaluation of genetic disease testing, and the program is required to provide genetic screening and followup services for persons who have the screening. The program includes statewide screening of newborn children through the collection of blood samples, unless the parent or guardian objects on the grounds of religious beliefs or practices.
This bill would instead prohibit the department from both testing a newborn child unless the parent or guardian is fully informed, as specified, and from storing, retaining, or using for medical research a blood sample collected unless the parent or guardian has given fully provides informed consent, as specified. The bill would authorize a parent or guardian of a minor child and the newborn child, once he or she is at least 18 years of age, to request that the department destroy or not use for research purposes, or both, the blood sample, and the department would be required to do so. The bill would also require the department to prepare and provide informational materials, to be distributed as specified, regarding the newborn child blood sample collected pursuant to the program that includes, but is not limited to, information on storage, retention, and use of the blood sample, and the right of specified persons to request that the blood sample be destroyed or not used for research purposes, or both. The bill would require the department to prepare and provide a standard informed consent form, to be distributed as specified, that sets forth clearly and in detail specified information. includes, among other things, an explanation of the newborn child screening test and a space for the parent or legal guardian of the newborn child to indicate his or her consent to the storage, retention, and use of the blood sample for medical research.
Existing law requires the State Department of Public Health to establish a program for the development, provision, and evaluation of genetic disease testing, and the program is required to provide genetic screening and followup services for persons who have the screening. The program includes statewide screening of newborn children through the collection of blood samples, unless the parent or guardian objects on the grounds of religious beliefs or practices.
This bill would instead prohibit the department from both testing a newborn child and storing, retaining, or using a blood sample collected unless the parent or guardian has given fully informed consent, as specified. The bill authorize a parent or guardian of a minor child and the newborn child, once he or she is legally an adult, at least 18 years of age, to request that the department destroy, destroy or not use for research purposes, or both, the blood sample, and the department would be required to do so. The bill would also require the department to prepare and provide informational materials, to be distributed as specified, regarding the newborn child blood sample collected pursuant to the program that includes, but is not limited to, information on storage, retention, and use of the blood sample, and the right of specified persons to request that the blood sample be destroyed, destroyed or not used for research purposes, or both. The bill would require the department to prepare and provide a standard informed consent form, to be distributed as specified, that sets forth clearly and in detail specified information.
Existing law requires the State Department of Public Health to establish a program for the development, provision, and evaluation of genetic disease testing, and the program is required to provide genetic screening and followup services for persons who have the screening. The program includes statewide screening of newborn children through the collection of blood samples, unless the parent or guardian objects on the grounds of religious beliefs or practices.
This bill would authorize a parent or guardian of a minor child and the newborn child, once he or she is legally an adult, to request that the department destroy, not use for research purposes, or both, the blood sample, and the department would be required to do so. The bill would also require the department to prepare and provide informational materials, to be distributed as specified, regarding the newborn child blood sample collected pursuant to the program that includes, but is not limited to, information on storage, retention, and use of the blood sample, and the right of specified persons to request that the blood sample be destroyed, not used for research purposes, or both.
(a)(1)It is the policy of the State of California to make every effort to detect, as early as possible, phenylketonuria and other preventable heritable or congenital disorders leading to intellectual disability or physical defects.
(2)The department shall establish a genetic disease unit, that shall coordinate all programs of the department in the area of genetic disease. The unit shall promote a statewide program of information, testing, and counseling services and shall have the responsibility of designating tests and regulations to be used in executing this program.
(3)The information, tests, and counseling for children shall be in accordance with accepted medical practices and shall be administered to each child born in California. The department shall provide information about the tests and shall obtain a signed informational acknowledgment form for the receipt of information by the parent or guardian of a newborn child regarding the storage, retention, and use of the newborn childs blood sample for medical research. The department shall establish appropriate regulations and testing methods. The information, tests, and counseling for pregnant women shall be in accordance with accepted medical practices and shall be offered to each pregnant woman in California once the department has established appropriate regulations and testing methods. These regulations shall follow the standards and principles specified in Section 124980. The department may provide laboratory testing facilities or contract with any laboratory that it deems qualified to conduct tests required under this section. However, notwithstanding former Section 125005, provision of laboratory testing facilities by the department shall be contingent upon the provision of funding therefor by specific appropriation to the Genetic Disease Testing Fund enacted by the Legislature. If moneys appropriated for purposes of this section are not authorized for expenditure to provide laboratory facilities, the department may nevertheless contract to provide laboratory testing services pursuant to this section and shall perform laboratory services, including, but not limited to, quality control, confirmatory, and emergency testing, necessary to ensure the objectives of this program.
(b)The department shall charge a fee for any tests performed pursuant to this section. The amount of the fee shall be established and periodically adjusted by the director in order to meet the reasonable costs of this section.
(c)The department shall inform all hospitals or physicians and surgeons, or both, of required regulations and tests and may alter or withdraw any of these requirements whenever sound medical practice so indicates. To the extent practicable, the department shall provide notice to hospitals and other payers in advance of an increase in the fees charged for the program.
(d)This section shall not apply if a parent or guardian of a newborn child objects to a test on the ground that the test conflicts with his or her religious beliefs or practices.
(e)The genetic disease unit is authorized to make grants or contracts or payments to vendors approved by the department for all of the following:
(1)Testing and counseling services.
(2)Demonstration projects to determine the desirability and feasibility of additional tests or new genetic services.
(3)To initiate the development of genetic services in areas of need.
(4)To purchase or provide genetic services from any sums as are appropriated for this purpose.
(f)(1)The genetic disease unit shall evaluate and prepare recommendations on the implementation of tests for the detection of hereditary and congenital diseases, including, but not limited to, biotinidase deficiency and cystic fibrosis. The genetic disease unit shall also evaluate and prepare recommendations on the availability and effectiveness of preventative followup interventions, including the use of specialized medically necessary dietary products.
(2)It is the intent of the Legislature that funds for the support of the evaluations and recommendations required pursuant to this subdivision, and for the activities authorized pursuant to subdivision (e), shall be provided in the annual Budget Act appropriation from the Genetic Disease Testing Fund.
(g)Health care providers that contract with a prepaid group practice health care service plan that annually has at least 20,000 births among its membership, may provide, without contracting with the department, any or all of the testing and counseling services required to be provided under this section or the regulations adopted pursuant thereto, if the services meet the quality standards and adhere to the regulations established by the department, the plan pays that portion of a fee established under this section that is directly attributable to the departments reasonable cost of administering the testing or counseling service and attributable to any required testing or counseling services provided by the state for plan members. The payment by the plan, as provided in this subdivision, shall be deemed to fulfill any obligation the provider or the providers patient may have to the department to pay a fee in connection with the testing or counseling service.
(h)The department may appoint experts in the area of genetic screening, including, but not limited to, cytogenetics, molecular biology, prenatal, specimen collection, and ultrasound, to provide expert advice and opinion on the interpretation and enforcement of regulations adopted pursuant to this section. These experts shall be designated agents of the state with respect to their assignments. These experts shall not receive a salary, but shall be reimbursed for expenses associated with the purposes of this section. All expenses of the experts for the purposes of this section shall be paid from the Genetic Disease Testing Fund.
(i)A parent or legal guardian of a minor may request the department to destroy the blood sample of the minor collected as a newborn, or not use it for research purposes, or both, and the department shall comply with that request. If the parent or legal guardian making the request provides his or her e-mail address, the department shall send an e-mail acknowledging that the department received the request.
(j)An individual who is at least 18 years of age may request the department to destroy his or her blood sample that was collected as a newborn, or not use it for research purposes, or both, and the department shall comply with that request. If the individual making the request provides his or her e-mail address, the department shall send an e-mail acknowledging that the department received the request.
SEC. 2.Section 125003 is added to the Health and Safety Code, to read:125003.(a)The department shall prepare and provide informational materials regarding newborn child blood samples collected pursuant to this article that include, but are not limited to, all of the following:
(1)A brief, plain language explanation of, and the purpose for, the newborn child screening test and the storage, retention, and use of newborn child blood samples collected pursuant to this article.
(2)A description of the benefits of both early newborn child screening and the associated research undertaken regarding preventable heritable or congenital disorders.
(3)A description of the California Biobank Program, specifically as it pertains to the Genetic Disease Screening Program, and subsequent storage, retention, and use of the newborn childs blood sample for medical research.
(4)An explanation of the parents or legal guardians right to request that his or her minor childs blood sample be destroyed or not used for research purposes, or both, and the information necessary to make that request.
(5)A statement that an individual who is at least 18 years of age has the right to request that his or her blood sample be destroyed or not used for research purposes, or both, and the information necessary to make that request.
(b)These informational materials shall be confined to a single page and presented in a separate document from the standard informational acceptance form required in Section 125004.
SEC. 3.Section 125004 is added to the Health and Safety Code, to read:125004.(a)The department shall prepare a standard informational acceptance form that includes all of the following:
(1)A brief, plain language explanation of, and the purpose for, the newborn child screening test and retention of newborn child blood samples collected pursuant to this article.
(2)An explanation of the parents or legal guardians right to request that his or her minor childs blood sample be destroyed or not used for research purposes, or both, and the information necessary to make that request.
(3)A space for the parent or legal guardian of the newborn child to acknowledge receipt of informational materials regarding the storage, retention, and use of the newborn childs blood sample for medical research.
(4)A space for the parent or legal guardian of the newborn child to sign and date the form.
(b)The standard informational acceptance form shall be confined to a single page and presented in a separate document from the informational materials required in Section 125003.
(c)A copy of the standard informational acceptance form shall be maintained in the medical record of the mother of the newborn child.
(d)As used in this article, informational acceptance form means a written acknowledgment of received informational materials, signed and dated by a parent or legal guardian of a newborn child.
(e)In the event that there is no signed standard informational acceptance form retained in the mothers medical record, the newborn child shall be administered the genetic screening test and the newborn child blood sample shall be stored and retained for medical research pursuant to Section 125000.
SEC. 4.Section 125005 is added to the Health and Safety Code, to read:125005.(a)The department shall provide a parent or legal guardian with the informational materials described in Section 125003 and the standard informational acceptance form described in Section 125004 regarding the retention of newborn child blood samples collected pursuant to this article.
(b)The informational materials and standard informational acceptance form described in Section 125004 shall be distributed as follows:
(1)A birth attendant engaged in providing perinatal care shall provide a pregnant woman, prior to the estimated date of delivery, with a copy of the informational materials and a copy of the standard informational acceptance form provided by the department.
(2)If the informational materials or standard informational acceptance form has not been provided pursuant to paragraph (1), a perinatal licensed health facility shall provide each pregnant woman admitted for delivery with a copy of the informational materials and a copy of the standard informational acceptance form provided by the department.
(3)The local registrar of births and deaths shall provide a copy of the informational material and a copy of the standard informational acceptance form provided by the department to each person registering the birth of a newborn that occurred outside of a perinatal licensed health facility when the newborn was not admitted to a perinatal licensed health facility within the first 30 days of age. The local registrar of births and deaths shall notify the local health officer and the department of each of these registrations.
(c)For the purposes of this section, the following terms shall have the following meanings:
(1)Birth attendant means a person licensed or certified by the state to provide maternity care and to deliver pregnant women or to practice medicine.
(2)Perinatal licensed health facility means a health facility licensed by the state and approved to provide perinatal, delivery, newborn intensive care, newborn nursery, or pediatric services.
SEC. 5.If the Commission on State Mandates determines that this act contains costs mandated by the state, reimbursement to local agencies and school districts for those costs shall be made pursuant to Part 7 (commencing with Section 17500) of Division 4 of Title 2 of the Government Code.
(a)(1)It is the policy of the State of California to make every effort to detect, as early as possible, phenylketonuria and other preventable heritable or congenital disorders leading to intellectual disability or physical defects.
(2)The department shall establish a genetic disease unit, that shall coordinate all programs of the department in the area of genetic disease. The unit shall promote a statewide program of information, testing, and counseling services and shall have the responsibility of designating tests and regulations to be used in executing this program.
(3)The information, tests, and counseling for children shall be in accordance with accepted medical practices and shall be administered to each child born in California. The department shall provide information about the tests and shall obtain a signed informational acknowledgment form for the receipt of information by the parent or guardian of a newborn child regarding the storage, retention, and use of the newborn childs blood sample for medical research. The department shall establish appropriate regulations and testing methods. The information, tests, and counseling for pregnant women shall be in accordance with accepted medical practices and shall be offered to each pregnant woman in California once the department has established appropriate regulations and testing methods. These regulations shall follow the standards and principles specified in Section 124980. The department may provide laboratory testing facilities or contract with any laboratory that it deems qualified to conduct tests required under this section. However, notwithstanding former Section 125005, provision of laboratory testing facilities by the department shall be contingent upon the provision of funding therefor by specific appropriation to the Genetic Disease Testing Fund enacted by the Legislature. If moneys appropriated for purposes of this section are not authorized for expenditure to provide laboratory facilities, the department may nevertheless contract to provide laboratory testing services pursuant to this section and shall perform laboratory services, including, but not limited to, quality control, confirmatory, and emergency testing, necessary to ensure the objectives of this program.
(b)The department shall charge a fee for any tests performed pursuant to this section. The amount of the fee shall be established and periodically adjusted by the director in order to meet the reasonable costs of this section.
(c)The department shall inform all hospitals or physicians and surgeons, or both, of required regulations and tests and may alter or withdraw any of these requirements whenever sound medical practice so indicates. To the extent practicable, the department shall provide notice to hospitals and other payers in advance of an increase in the fees charged for the program.
(d)This section shall not apply if a parent or guardian of a newborn child objects to a test on the ground that the test conflicts with his or her religious beliefs or practices.
(e)The genetic disease unit is authorized to make grants or contracts or payments to vendors approved by the department for all of the following:
(1)Testing and counseling services.
(2)Demonstration projects to determine the desirability and feasibility of additional tests or new genetic services.
(3)To initiate the development of genetic services in areas of need.
(4)To purchase or provide genetic services from any sums as are appropriated for this purpose.
(f)(1)The genetic disease unit shall evaluate and prepare recommendations on the implementation of tests for the detection of hereditary and congenital diseases, including, but not limited to, biotinidase deficiency and cystic fibrosis. The genetic disease unit shall also evaluate and prepare recommendations on the availability and effectiveness of preventative followup interventions, including the use of specialized medically necessary dietary products.
(2)It is the intent of the Legislature that funds for the support of the evaluations and recommendations required pursuant to this subdivision, and for the activities authorized pursuant to subdivision (e), shall be provided in the annual Budget Act appropriation from the Genetic Disease Testing Fund.
(g)Health care providers that contract with a prepaid group practice health care service plan that annually has at least 20,000 births among its membership, may provide, without contracting with the department, any or all of the testing and counseling services required to be provided under this section or the regulations adopted pursuant thereto, if the services meet the quality standards and adhere to the regulations established by the department, the plan pays that portion of a fee established under this section that is directly attributable to the departments reasonable cost of administering the testing or counseling service and attributable to any required testing or counseling services provided by the state for plan members. The payment by the plan, as provided in this subdivision, shall be deemed to fulfill any obligation the provider or the providers patient may have to the department to pay a fee in connection with the testing or counseling service.
(h)The department may appoint experts in the area of genetic screening, including, but not limited to, cytogenetics, molecular biology, prenatal, specimen collection, and ultrasound, to provide expert advice and opinion on the interpretation and enforcement of regulations adopted pursuant to this section. These experts shall be designated agents of the state with respect to their assignments. These experts shall not receive a salary, but shall be reimbursed for expenses associated with the purposes of this section. All expenses of the experts for the purposes of this section shall be paid from the Genetic Disease Testing Fund.
(i)A parent or legal guardian of a minor may request the department destroy the blood sample of the minor collected as a newborn, or not use it for research purposes, or both, and the department shall comply with that request.
(j)An individual who is at least 18 years of age may request the department destroy his or her blood sample that was collected as a newborn, or not use it for research purposes, or both, and the department shall comply with that request.
SEC. 2.Section 125003 is added to the Health and Safety Code, to read:125003.(a)The department shall prepare and provide informational materials regarding newborn child blood samples collected pursuant to this article that include, but are not limited to, all of the following:
(1)Storage, retention, and use of the blood sample.
(2)The parent or legal guardians right to request that his or her minor childs blood sample be destroyed or not used for research purposes, or both, and the information necessary to make that request.
(3)The right of an individual who is at least 18 years of age to request that his or her blood sample be destroyed or not used for research purposes, or both, and the information necessary to make that request.
(b)These informational materials shall be confined to a single page and presented in a separate document from informational materials pertaining to the newborn screening program.
(c)The department shall provide to a parent or legal guardian the standard informational acceptance form provided in Section 125004 regarding the retention of newborn child blood samples collected pursuant to this article.
(d)The informational materials and the standard informational acceptance form prepared and provided by the department shall be distributed as follows:
(1)Every birth attendant engaged in providing perinatal care shall provide a pregnant woman, prior to the estimated date of delivery, with a copy of the informational materials and a copy of the standard informational acceptance form provided by the department.
(2)Every perinatal licensed health facility shall provide each pregnant woman admitted for delivery with a copy of the informational materials and a copy of the standard informational acceptance form provided by the department, prior to collection of the blood sample, if that information or standard informational acceptance form has not been provided pursuant to paragraph (1).
(3)The local registrar of births shall provide a copy of the informational material and a copy of the standard informational acceptance form provided by the department to each person registering the birth of a newborn that occurred outside of a perinatal licensed health facility when the newborn was not admitted to a perinatal licensed health facility within the first 30 days of age. The local health officer and the department shall be notified of each of these registrations by the local registrar.
(e)For the purposes of this section, the following terms shall have the following meanings:
(1)Birth attendant means a person licensed or certified by the state to provide maternity care and to deliver pregnant women or to practice medicine.
(2)Perinatal licensed health facility means a health facility licensed by the state and approved to provide perinatal, delivery, newborn intensive care, newborn nursery, or pediatric services.
(1)A brief, plain language explanation of, and the purpose for, the newborn child screening test and the storage, retention, and use of newborn child blood samples collected pursuant to this article.
(2)A description of the benefits of both early newborn child screening and the associated research undertaken regarding preventable heritable or congenital disorders.
(3)A description of the California Biobank Program, specifically as it pertains to the Genetic Disease Screening Program, and subsequent storage, retention, and use of the newborn childs blood sample for medical research.
(4)An explanation of the parents or legal guardians right to request that his or her minor childs blood sample be destroyed or not used for research purposes, or both, and the information necessary to make that request.
(5)A statement that an individual who is at least 18 years of age has the right to request that his or her blood sample be destroyed or not used for research purposes, or both, and the information necessary to make that request.
(b)These informational materials shall be confined to a single page and presented in a separate document from the standard informational acceptance form required in Section 125004.
SEC. 3.Section 125004 is added to the Health and Safety Code, to read:125004.(a)The department shall prepare a standard informational acceptance form that includes all of the following:
(1)A brief, plain language explanation of, and the purpose for, the newborn child screening test and retention of newborn child blood samples collected pursuant to this article.
(2)A description of the benefits of both early newborn child screening and the associated research undertaken regarding preventable heritable or congenital disorders.
(3)A description of the California Biobank Program, specifically as it pertains to the Genetic Disease Screening Program, and subsequent storage, retention, and use of the newborn childs blood sample for medical research.
(4)A space for the parent or legal guardian of the newborn child to acknowledge receipt of informational materials regarding the storage, retention, and use of the newborn childs blood sample for medical research.
(5)(a)A space for the parent or legal guardian of the newborn child to sign and date the form.
(b)A copy of the standard informational acceptance form shall be maintained with the medical records of the mother of the newborn child.
(c)As used in this article, informational acceptance form means a written acknowledgment of received informational materials, signed and dated by a parent or legal guardian of a newborn child.
(d)If there is no signed standard informational acceptance form retained in the mothers medical record, the newborn child shall still be administered the genetic screening test and the newborn child blood sample shall be stored and retained for medical research pursuant to Section 125000.
(2)An explanation of the parents or legal guardians right to request that his or her minor childs blood sample be destroyed or not used for research purposes, or both, and the information necessary to make that request.
(3)A space for the parent or legal guardian of the newborn child to acknowledge receipt of informational materials regarding the storage, retention, and use of the newborn childs blood sample for medical research.
(4)A space for the parent or legal guardian of the newborn child to sign and date the form.
(b)The standard informational acceptance form shall be confined to a single page and presented in a separate document from the informational materials required in Section 125003.
(c)A copy of the standard informational acceptance form shall be maintained in the medical record of the mother of the newborn child.
(d)As used in this article, informational acceptance form means a written acknowledgment of received informational materials, signed and dated by a parent or legal guardian of a newborn child.
(e)In the event that there is no signed standard informational acceptance form retained in the mothers medical record, the newborn child shall be administered the genetic screening test and the newborn child blood sample shall be stored and retained for medical research pursuant to Section 125000.
SEC. 4.Section 125005 is added to the Health and Safety Code, to read:125005.(a)The department shall provide a parent or legal guardian with the informational materials described in Section 125003 and the standard informational acceptance form described in Section 125004 regarding the retention of newborn child blood samples collected pursuant to this article.
(b)The informational materials and standard informational acceptance form described in Section 125004 shall be distributed as follows:
(1)A birth attendant engaged in providing perinatal care shall provide a pregnant woman, prior to the estimated date of delivery, with a copy of the informational materials and a copy of the standard informational acceptance form provided by the department.
(2)If the informational materials or standard informational acceptance form has not been provided pursuant to paragraph (1), a perinatal licensed health facility shall provide each pregnant woman admitted for delivery with a copy of the informational materials and a copy of the standard informational acceptance form provided by the department.
(3)The local registrar of births and deaths shall provide a copy of the informational material and a copy of the standard informational acceptance form provided by the department to each person registering the birth of a newborn that occurred outside of a perinatal licensed health facility when the newborn was not admitted to a perinatal licensed health facility within the first 30 days of age. The local registrar of births and deaths shall notify the local health officer and the department of each of these registrations.
(c)For the purposes of this section, the following terms shall have the following meanings:
(1)Birth attendant means a person licensed or certified by the state to provide maternity care and to deliver pregnant women or to practice medicine.
(2)Perinatal licensed health facility means a health facility licensed by the state and approved to provide perinatal, delivery, newborn intensive care, newborn nursery, or pediatric services.
SEC. 4.SEC. 5.If the Commission on State Mandates determines that this act contains costs mandated by the state, reimbursement to local agencies and school districts for those costs shall be made pursuant to Part 7 (commencing with Section 17500) of Division 4 of Title 2 of the Government Code.
(a)(1)It is the policy of the State of California to make every effort to detect, as early as possible, phenylketonuria and other preventable heritable or congenital disorders leading to intellectual disability or physical defects.
(2)The department shall establish a genetic disease unit, that shall coordinate all programs of the department in the area of genetic disease. The unit shall promote a statewide program of information, testing, and counseling services and shall have the responsibility of designating tests and regulations to be used in executing this program.
(3)The information, tests, and counseling for children shall be in accordance with accepted medical practices and shall be administered to each child born in California. The department shall provide information about the tests and shall obtain a signed informational acknowledgment form for the receipt of information by the parent or guardian of a newborn child regarding the storage, retention, and use of the newborn childs blood sample for medical research. The department shall establish appropriate regulations and testing methods. The information, tests, and counseling for pregnant women shall be in accordance with accepted medical practices and shall be offered to each pregnant woman in California once the department has established appropriate regulations and testing methods. These regulations shall follow the standards and principles specified in Section 124980. The department may provide laboratory testing facilities or contract with any laboratory that it deems qualified to conduct tests required under this section. However, notwithstanding former Section 125005, provision of laboratory testing facilities by the department shall be contingent upon the provision of funding therefor by specific appropriation to the Genetic Disease Testing Fund enacted by the Legislature. If moneys appropriated for purposes of this section are not authorized for expenditure to provide laboratory facilities, the department may nevertheless contract to provide laboratory testing services pursuant to this section and shall perform laboratory services, including, but not limited to, quality control, confirmatory, and emergency testing, necessary to ensure the objectives of this program.
(b)The department shall charge a fee for any tests performed pursuant to this section. The amount of the fee shall be established and periodically adjusted by the director in order to meet the reasonable costs of this section.
(c)The department shall inform all hospitals or physicians and surgeons, or both, of required regulations and tests and may alter or withdraw any of these requirements whenever sound medical practice so indicates. To the extent practicable, the department shall provide notice to hospitals and other payers in advance of an increase in the fees charged for the program.
(d)This section shall not apply to if a parent or guardian of a newborn child who objects to a test. test on the ground that the test conflicts with his or her religious beliefs or practices.
(e)The genetic disease unit is authorized to make grants or contracts or payments to vendors approved by the department for all of the following:
(1)Testing and counseling services.
(2)Demonstration projects to determine the desirability and feasibility of additional tests or new genetic services.
(3)To initiate the development of genetic services in areas of need.
(4)To purchase or provide genetic services from any sums as are appropriated for this purpose.
(f)(1)The genetic disease unit shall evaluate and prepare recommendations on the implementation of tests for the detection of hereditary and congenital diseases, including, but not limited to, biotinidase deficiency and cystic fibrosis. The genetic disease unit shall also evaluate and prepare recommendations on the availability and effectiveness of preventative followup interventions, including the use of specialized medically necessary dietary products.
(2)It is the intent of the Legislature that funds for the support of the evaluations and recommendations required pursuant to this subdivision, and for the activities authorized pursuant to subdivision (e), shall be provided in the annual Budget Act appropriation from the Genetic Disease Testing Fund.
(g)Health care providers that contract with a prepaid group practice health care service plan that annually has at least 20,000 births among its membership, may provide, without contracting with the department, any or all of the testing and counseling services required to be provided under this section or the regulations adopted pursuant thereto, if the services meet the quality standards and adhere to the regulations established by the department, the plan pays that portion of a fee established under this section that is directly attributable to the departments reasonable cost of administering the testing or counseling service and attributable to any required testing or counseling services provided by the state for plan members. The payment by the plan, as provided in this subdivision, shall be deemed to fulfill any obligation the provider or the providers patient may have to the department to pay a fee in connection with the testing or counseling service.
(h)The department may appoint experts in the area of genetic screening, including, but not limited to, cytogenetics, molecular biology, prenatal, specimen collection, and ultrasound, to provide expert advice and opinion on the interpretation and enforcement of regulations adopted pursuant to this section. These experts shall be designated agents of the state with respect to their assignments. These experts shall not receive a salary, but shall be reimbursed for expenses associated with the purposes of this section. All expenses of the experts for the purposes of this section shall be paid from the Genetic Disease Testing Fund.
(i)A parent or legal guardian of a minor may request the department destroy the blood sample of the minor collected as a newborn, or not use it for research purposes, or both, and the department shall comply with that request.
(j)An individual who is at least 18 years of age may request the department destroy his or her blood sample that was collected as a newborn, or not use it for research purposes, or both, and the department shall comply with that request.
SEC. 2.Section 125003 is added to the Health and Safety Code, to read:125003.(a)The department shall prepare and provide informational materials regarding newborn child blood samples collected pursuant to this article that include, but are not limited to, all of the following:
(1)Storage, retention, and use of the blood sample.
(2)The parent or legal guardians right to request that his or her minor childs blood sample be destroyed or not used for research purposes, or both, and the information necessary to make that request.
(3)The right of an individual who is at least 18 years of age to request that his or her blood sample be destroyed or not used for research purposes, or both, and the information necessary to make that request.
(b)These informational materials shall be confined to a single page and presented in a separate document from informational materials pertaining to the newborn screening program.
(c)The department shall provide to a parent or legal guardian the standard informational acceptance form provided in Section 125004 regarding the options for newborn child screening and retention of newborn child blood samples collected pursuant to this article.
(d)The informational materials and the standard informational acceptance form prepared and provided by the department shall be distributed as follows:
(1)Every birth attendant engaged in providing perinatal care shall provide a pregnant woman, prior to the estimated date of delivery, with a copy of the informational materials and a copy of the standard informational acceptance form provided by the department.
(2)Every perinatal licensed health facility shall provide each pregnant woman admitted for delivery with a copy of the informational materials and a copy of the standard informational acceptance form provided by the department, prior to collection of the blood sample, if that information or standard informational acceptance form has not been provided pursuant to paragraph (1).
(3)The local registrar of births shall provide a copy of the informational material and a copy of the standard informational acceptance form provided by the department to each person registering the birth of a newborn that occurred outside of a perinatal licensed health facility when the newborn was not admitted to a perinatal licensed health facility within the first 30 days of age. The local health officer and the department shall be notified of each of these registrations by the local registrar.
(d)
(e)For the purposes of this section, the following terms shall have the following meanings:
(1)Birth attendant means a person licensed or certified by the state to provide maternity care and to deliver pregnant women or to practice medicine.
(2)Perinatal licensed health facility means a health facility licensed by the state and approved to provide perinatal, delivery, newborn intensive care, newborn nursery, or pediatric services.
SEC. 3.Section 125004 is added to the Health and Safety Code, to read:125004.(a)The department shall prepare a standard informational acceptance form that includes all of the following:
(1)A brief, plain language explanation of, and the purpose for, the newborn child screening test and retention of newborn child blood samples collected pursuant to this article.
(2)A description of the benefits of both early newborn child screening and the associated research undertaken regarding preventable heritable or congenital disorders.
(3)A description of the California Biobank Program, specifically as it pertains to the Genetic Disease Screening Program, and subsequent storage, retention, and use of the newborn childs blood sample for medical research.
(4)A space for the parent or legal guardian of the newborn child to acknowledge receipt of informational materials regarding the newborn child screening test, and the storage, retention, and use of the newborn childs blood sample for medical research.
(5)(a)A space for the parent or legal guardian of the newborn child to sign and date the form.
(b)A copy of the standard informational acceptance form shall be maintained with the newborn childs medical records. medical records of the mother of the newborn child.
(c)As used in this article, informational acceptance form means a written acknowledgment of received informational materials, signed and dated by a parent or legal guardian of a newborn child.
(d)If there is no signed standard informational acceptance form retained in the mothers medical record, the newborn child shall still be administered the genetic screening test and the newborn child blood sample shall be stored and retained for medical research pursuant to Section 125000.
SEC. 4.If the Commission on State Mandates determines that this act contains costs mandated by the state, reimbursement to local agencies and school districts for those costs shall be made pursuant to Part 7 (commencing with Section 17500) of Division 4 of Title 2 of the Government Code.
(a)(1)It is the policy of the State of California to make every effort to detect, as early as possible, phenylketonuria and other preventable heritable or congenital disorders leading to intellectual disability or physical defects.
(2)The department shall establish a genetic disease unit, that shall coordinate all programs of the department in the area of genetic disease. The unit shall promote a statewide program of information, testing, and counseling services and shall have the responsibility of designating tests and regulations to be used in executing this program.
(3)The information, tests, and counseling for children shall be in accordance with accepted medical practices and shall be administered to each child born in California. The department shall provide information about the tests and shall obtain the informed consent of a signed informational acknowledgment form for the receipt of information by the parent or guardian of a newborn child for regarding the storage, retention, and use of the newborn childs blood sample for medical research. The department shall establish appropriate regulations and testing methods. The information, tests, and counseling for pregnant women shall be in accordance with accepted medical practices and shall be offered to each pregnant woman in California once the department has established appropriate regulations and testing methods. These regulations shall follow the standards and principles specified in Section 124980. The department may provide laboratory testing facilities or contract with any laboratory that it deems qualified to conduct tests required under this section. However, notwithstanding former Section 125005, provision of laboratory testing facilities by the department shall be contingent upon the provision of funding therefor by specific appropriation to the Genetic Disease Testing Fund enacted by the Legislature. If moneys appropriated for purposes of this section are not authorized for expenditure to provide laboratory facilities, the department may nevertheless contract to provide laboratory testing services pursuant to this section and shall perform laboratory services, including, but not limited to, quality control, confirmatory, and emergency testing, necessary to ensure the objectives of this program.
(b)The department shall charge a fee for any tests performed pursuant to this section. The amount of the fee shall be established and periodically adjusted by the director in order to meet the reasonable costs of this section.
(c)The department shall inform all hospitals or physicians and surgeons, or both, of required regulations and tests and may alter or withdraw any of these requirements whenever sound medical practice so indicates. To the extent practicable, the department shall provide notice to hospitals and other payers in advance of an increase in the fees charged for the program.
(d)(1)A test shall not be performed on any newborn child unless the parent or guardian is fully informed of the purpose and benefits of testing for preventable heritable and congenital disorders and is given a reasonable opportunity to refuse a newborn child screening test on the ground that the test conflicts with his or her religious beliefs or practices.
(2)A newborn child blood sample shall not be stored, retained, and used by the department for medical research unless the parent or guardian is fully informed of the benefits of research regarding preventing heritable and congenital disorders and provides informed consent to the storage, retention, and use of the newborn child blood sample collected.
(d)This section shall not apply to a parent or guardian of a newborn child who objects to a test.
(e)The genetic disease unit is authorized to make grants or contracts or payments to vendors approved by the department for all of the following:
(1)Testing and counseling services.
(2)Demonstration projects to determine the desirability and feasibility of additional tests or new genetic services.
(3)To initiate the development of genetic services in areas of need.
(4)To purchase or provide genetic services from any sums as are appropriated for this purpose.
(f)(1)The genetic disease unit shall evaluate and prepare recommendations on the implementation of tests for the detection of hereditary and congenital diseases, including, but not limited to, biotinidase deficiency and cystic fibrosis. The genetic disease unit shall also evaluate and prepare recommendations on the availability and effectiveness of preventative followup interventions, including the use of specialized medically necessary dietary products.
It
(2)It is the intent of the Legislature that funds for the support of the evaluations and recommendations required pursuant to this subdivision, and for the activities authorized pursuant to subdivision (e), shall be provided in the annual Budget Act appropriation from the Genetic Disease Testing Fund.
(g)Health care providers that contract with a prepaid group practice health care service plan that annually has at least 20,000 births among its membership, may provide, without contracting with the department, any or all of the testing and counseling services required to be provided under this section or the regulations adopted pursuant thereto, if the services meet the quality standards and adhere to the regulations established by the department and department, the plan pays that portion of a fee established under this section that is directly attributable to the departments reasonable cost of administering the testing or counseling service and attributable to any required testing or counseling services provided by the state for plan members. The payment by the plan, as provided in this subdivision, shall be deemed to fulfill any obligation the provider or the providers patient may have to the department to pay a fee in connection with the testing or counseling service.
(h)The department may appoint experts in the area of genetic screening, including, but not limited to, cytogenetics, molecular biology, prenatal, specimen collection, and ultrasound, to provide expert advice and opinion on the interpretation and enforcement of regulations adopted pursuant to this section. These experts shall be designated agents of the state with respect to their assignments. These experts shall not receive no a salary, but shall be reimbursed for expenses associated with the purposes of this section. All expenses of the experts for the purposes of this section shall be paid from the Genetic Disease Testing Fund.
(i)A parent or legal guardian of a minor may request the department to destroy the blood sample of the minor collected as a newborn, or not use it for research purposes, or both, the blood sample of the minor collected as a newborn, and the department shall do so. comply with that request.
(j)An individual who is at least 18 years of age may request the department to destroy his or her blood sample that was collected as a newborn, or not use it for research purposes, or both, his or her blood sample that was collected, and the department shall do so. comply with that request.
SEC. 2.Section 125003 is added to the Health and Safety Code, to read:125003.(a)The department shall prepare and provide informational materials regarding newborn child blood samples collected pursuant to this article that include, but are not limited to, all of the following:
(1)Storage, retention, and use of the blood sample.
(2)The parent or legal guardians right to request that his or her minor childs blood sample be destroyed or not used for research purposes, or both, and the information necessary to make that request.
(3)The right of an individual who is at least 18 years of age to request that his or her blood sample be destroyed or not used for research purposes, or both, and the information necessary to make that request.
(b)These informational materials shall be confined to a single page and presented in a separate document from informational materials pertaining to the newborn screening program.
(b)
(c)The department shall provide to a parent or legal guardian the standard informed consent informational acceptance form provided in Section 125004 regarding the options for newborn child screening and retention of newborn child blood samples collected pursuant to this article.
(c)
(d)The informational materials and the standard informed consent informational acceptance form prepared and provided by the department shall be distributed as follows:
(1)Every birth attendant engaged in providing perinatal care shall provide a pregnant woman, prior to the estimated date of delivery, with a copy of the informational materials and a copy of the standard informed consent informational acceptance form provided by the department.
(2)Every perinatal licensed health facility shall provide each pregnant woman admitted for delivery with a copy of the informational materials and a copy of the standard informed consent informational acceptance form provided by the department, prior to collection of the blood sample, if that information or standard informed consent informational acceptance form has not been provided pursuant to paragraph (1).
(3)The local registrar of births shall provide a copy of the informational material and a copy of the standard informed consent informational acceptance form provided by the department to each person registering the birth of a newborn that occurred outside of a perinatal licensed health facility when the newborn was not admitted to a perinatal licensed health facility within the first 30 days of age. The local health officer and the department shall be notified of each of these registrations by the local registrar.
(d)For the purposes of this section, the following terms shall have the following meanings:
(1)Birth attendant means a person licensed or certified by the state to provide maternity care and to deliver pregnant women or to practice medicine.
(2)Perinatal licensed health facility means a health facility licensed by the state and approved to provide perinatal, delivery, newborn intensive care, newborn nursery, or pediatric services.
SEC. 3.Section 125004 is added to the Health and Safety Code, to read:125004.(a)The department shall prepare a standard informed consent informational acceptance form that includes all of the following:
(1)A brief, plain language explanation of, and the purpose for, the newborn child screening test and retention of newborn child blood samples collected pursuant to this article.
(2)A description of the benefits of both early newborn child screening and the associated research undertaken regarding preventable heritable or congenital disorders.
(3)A description of the California Biobank Program, specifically as it pertains to the Genetic Disease Screening Program, and subsequent storage, retention, and use of the newborn childs blood sample for medical research.
(3)
(4)A space for the parent or legal guardian of the newborn child to acknowledge receipt of informational materials regarding the newborn child screening test, and the storage, retention, and use of the newborn childs blood sample for medical research.
(4)A space for the parent or legal guardian of the newborn child to indicate his or her consent to the storage, retention, and use of the blood sample for medical research.
(5)A space for the parent or legal guardian of the newborn child to indicate his or her request for information about the right to refuse a newborn child screening test on the ground that the test conflicts with his or her religious beliefs or practices.
(6)
(5)(a)A space for the parent or legal guardian of the newborn child to sign and date the form.
(b)The department shall not store, retain, or use for medical research a newborn childs blood sample collected and used for the newborn screening test unless the parent or guardian of the newborn child has first indicated his or her consent on the completed standard informed consent form.
(c)
(b)A copy of the standard informed consent informational acceptance form shall be maintained with the newborn childs medical records.
(d)
(c)As used in this article, informed consent informational acceptance form means a written authorization acknowledgment of received informational materials, signed and dated by a parent or legal guardian of a newborn child.
SEC. 4.If the Commission on State Mandates determines that this act contains costs mandated by the state, reimbursement to local agencies and school districts for those costs shall be made pursuant to Part 7 (commencing with Section 17500) of Division 4 of Title 2 of the Government Code.
(a)(1)It is the policy of the State of California to make every effort to detect, as early as possible, phenylketonuria and other preventable heritable or congenital disorders leading to intellectual disability or physical defects.
The
(2)The department shall establish a genetic disease unit, that shall coordinate all programs of the department in the area of genetic disease. The unit shall promote a statewide program of information, testing, and counseling services and shall have the responsibility of designating tests and regulations to be used in executing this program.
The
(3)The information, tests, and counseling for children shall be in accordance with accepted medical practices and shall be administered to each child born in California if the fully California. The department shall provide information about the tests and shall obtain the informed consent of the parent or guardian of a newborn child is obtained and once the department has established for the storage, retention, and use of the newborn childs blood sample for medical research. The department shall establish appropriate regulations and testing methods. The information, tests, and counseling for pregnant women shall be in accordance with accepted medical practices and shall be offered to each pregnant woman in California once the department has established appropriate regulations and testing methods. These regulations shall follow the standards and principles specified in Section 124980. The department may provide laboratory testing facilities or contract with any laboratory that it deems qualified to conduct tests required under this section. However, notwithstanding former Section 125005, provision of laboratory testing facilities by the department shall be contingent upon the provision of funding therefor by specific appropriation to the Genetic Disease Testing Fund enacted by the Legislature. If moneys appropriated for purposes of this section are not authorized for expenditure to provide laboratory facilities, the department may nevertheless contract to provide laboratory testing services pursuant to this section and shall perform laboratory services, including, but not limited to, quality control, confirmatory, and emergency testing, necessary to ensure the objectives of this program.
(b)The department shall charge a fee for any tests performed pursuant to this section. The amount of the fee shall be established and periodically adjusted by the director in order to meet the costs of this section.
(c)The department shall inform all hospitals or physicians and surgeons, or both, of required regulations and tests and may alter or withdraw any of these requirements whenever sound medical practice so indicates. To the extent practicable, the department shall provide notice to hospitals and other payers in advance of an increase in the fees charged for the program.
(d)(1)A test shall not be performed on any newborn child unless the parent or guardian is fully informed of the purpose and benefits of testing for preventable heritable and congenital disorders and is given a reasonable opportunity to refuse a newborn child screening test on the ground that the test conflicts with his or her religious beliefs or practices.
(2)A newborn child blood sample shall not be stored, retained, and used by the department for medical research unless the parent or guardian is fully informed of the benefits of research regarding preventing heritable and congenital disorders and is given a reasonable opportunity to object provides informed consent to the storage, retention, and use of the newborn child blood sample collected.
(e)The genetic disease unit is authorized to make grants or contracts or payments to vendors approved by the department for all of the following:
(1)Testing and counseling services.
(2)Demonstration projects to determine the desirability and feasibility of additional tests or new genetic services.
(3)To initiate the development of genetic services in areas of need.
(4)To purchase or provide genetic services from any sums as are appropriated for this purpose.
(f)The genetic disease unit shall evaluate and prepare recommendations on the implementation of tests for the detection of hereditary and congenital diseases, including, but not limited to, biotinidase deficiency and cystic fibrosis. The genetic disease unit shall also evaluate and prepare recommendations on the availability and effectiveness of preventative followup interventions, including the use of specialized medically necessary dietary products.
It is the intent of the Legislature that funds for the support of the evaluations and recommendations required pursuant to this subdivision, and for the activities authorized pursuant to subdivision (e), shall be provided in the annual Budget Act appropriation from the Genetic Disease Testing Fund.
(g)Health care providers that contract with a prepaid group practice health care service plan that annually has at least 20,000 births among its membership, may provide, without contracting with the department, any or all of the testing and counseling services required to be provided under this section or the regulations adopted pursuant thereto, if the services meet the quality standards and adhere to the regulations established by the department and the plan pays that portion of a fee established under this section that is directly attributable to the departments cost of administering the testing or counseling service and to any required testing or counseling services provided by the state for plan members. The payment by the plan, as provided in this subdivision, shall be deemed to fulfill any obligation the provider or the providers patient may have to the department to pay a fee in connection with the testing or counseling service.
(h)The department may appoint experts in the area of genetic screening, including, but not limited to, cytogenetics, molecular biology, prenatal, specimen collection, and ultrasound to provide expert advice and opinion on the interpretation and enforcement of regulations adopted pursuant to this section. These experts shall be designated agents of the state with respect to their assignments. These experts shall receive no salary, but shall be reimbursed for expenses associated with the purposes of this section. All expenses of the experts for the purposes of this section shall be paid from the Genetic Disease Testing Fund.
(i)A parent or legal guardian of a minor may request the department to destroy or not use for research purposes, or both, the blood sample of the minor collected as a newborn, and the department shall do so.
(j)An individual who is at least 18 years of age may request the department to destroy or not use for research purposes, or both, his or her blood sample that was collected, and the department shall do so.
SEC. 2.Section 125003 is added to the Health and Safety Code, to read:125003.(a)The department shall prepare and provide informational materials regarding newborn child blood samples collected pursuant to this article that include, but are not limited to, all of the following:
(1)Storage, retention, and use of the blood sample.
(2)The parent or legal guardians right to request that his or her minor childs blood sample be destroyed or not used for research purposes, or both, and the information necessary to make that request.
(3)The right of an individual who is at least 18 years of age to request that his or her blood sample be destroyed or not used for research purposes, or both, and the information necessary to make that request.
(b)The department shall provide to a parent or legal guardian the standard informed consent form provided in Section 125004 regarding the options for newborn child screening and retention of newborn child blood samples collected pursuant to this article.
(c)The informational materials and the standard informed consent form prepared and provided by the department shall be distributed as follows:
(1)Every birth attendant engaged in providing perinatal care shall provide a pregnant woman, prior to the estimated date of delivery, with a copy of the informational materials and a copy of the standard informed consent form provided by the department.
(2)Every perinatal licensed health facility shall provide each pregnant woman admitted for delivery with a copy of the informational materials and a copy of the standard informed consent form provided by the department, prior to collection of the blood sample, if that information or standard informed consent form has not been provided pursuant to paragraph (1).
(3)The local registrar of births shall provide a copy of the informational material and a copy of the standard informed consent form provided by the department to each person registering the birth of a newborn that occurred outside of a perinatal licensed health facility when the newborn was not admitted to a perinatal licensed health facility within the first 30 days of age. The local health officer and the department shall be notified of each of these registrations by the local registrar.
(d)For the purposes of this section, the following terms shall have the following meanings:
(1)Birth attendant means a person licensed or certified by the state to provide maternity care and to deliver pregnant women or to practice medicine.
(2)Perinatal licensed health facility means a health facility licensed by the state and approved to provide perinatal, delivery, newborn intensive care, newborn nursery, or pediatric services.
SEC. 3.Section 125004 is added to the Health and Safety Code, to read:125004.(a)The department shall prepare a standard informed consent form setting forth clearly and in detail that includes all of the following:
(1)A brief, plain language explanation of, and the purpose for, the newborn child screening test and retention of newborn child blood samples collected pursuant to this article.
(2)A description of the benefits of both early newborn child screening and the associated research undertaken regarding preventable heritable or congenital disorders.
(3)That A space for the parent or legal guardian of the newborn child may consent to acknowledge receipt of informational materials regarding the newborn child screening test.
(4)A space for the parent or legal guardian of the newborn child to indicate his or her consent to the storage, retention, and use of the blood sample for medical research.
(4)
(5)That A space for the parent or legal guardian of the newborn child has to indicate his or her request for information about the right to refuse a newborn child screening test on the ground that the test conflicts with his or her religious beliefs or practices.
(5)That if the parent or legal guardian of the newborn child refuses to have the newborn child screening test done, he or she accepts all responsibility and liability for the possible consequences.
(6)A description of the health risks associated with foregoing the newborn child screening test.
(7)That the parent or legal guardian of the newborn child may consent to the storage, retention, and use of the blood sample.
(8)That the parent or legal guardian of the newborn child may request the department to destroy or not use for research purposes, or both, the blood sample collected and screened.
(6)A space for the parent or legal guardian of the newborn child to sign and date the form.
(b)The department shall not store, retain, or use for medical research a newborn childs blood sample collected and used for the newborn screening test unless the parent or guardian of the newborn child has first indicated his or her consent on the completed standard informed consent form.
(b)
(c)A copy of the standard informed consent form shall be maintained with the newborn childs medical records.
(d)As used in this article, informed consent means a written authorization signed and dated by a parent or legal guardian of a newborn child.
(a)It is the policy of the State of California to make every effort to detect, as early as possible, phenylketonuria and other preventable heritable or congenital disorders leading to intellectual disability or physical defects.
The department shall establish a genetic disease unit, that shall coordinate all programs of the department in the area of genetic disease. The unit shall promote a statewide program of information, testing, and counseling services and shall have the responsibility of designating tests and regulations to be used in executing this program.
The information, tests, and counseling for children shall be in accordance with accepted medical practices and shall be administered to each child born in California if the fully informed consent of the parent or guardian of a newborn child is obtained and once the department has established appropriate regulations and testing methods. The information, tests, and counseling for pregnant women shall be in accordance with accepted medical practices and shall be offered to each pregnant woman in California once the department has established appropriate regulations and testing methods. These regulations shall follow the standards and principles specified in Section 124980. The department may provide laboratory testing facilities or contract with any laboratory that it deems qualified to conduct tests required under this section. However, notwithstanding former Section 125005, provision of laboratory testing facilities by the department shall be contingent upon the provision of funding therefor by specific appropriation to the Genetic Disease Testing Fund enacted by the Legislature. If moneys appropriated for purposes of this section are not authorized for expenditure to provide laboratory facilities, the department may nevertheless contract to provide laboratory testing services pursuant to this section and shall perform laboratory services, including, but not limited to, quality control, confirmatory, and emergency testing, necessary to ensure the objectives of this program.
(b)The department shall charge a fee for any tests performed pursuant to this section. The amount of the fee shall be established and periodically adjusted by the director in order to meet the costs of this section.
(c)The department shall inform all hospitals or physicians and surgeons, or both, of required regulations and tests and may alter or withdraw any of these requirements whenever sound medical practice so indicates. To the extent practicable, the department shall provide notice to hospitals and other payers in advance of an increase in the fees charged for the program.
(d)This section shall not apply if a parent or guardian of the newborn child objects to a test on the ground that the test conflicts with his or her religious beliefs or practices.
(d)(1)A test shall not be performed on any newborn child unless the parent or guardian is fully informed of the purpose and benefits of testing for preventable heritable and congenital disorders and is given a reasonable opportunity to refuse a newborn child screening test on the ground that the test conflicts with his or her religious beliefs or practices.
(2)A newborn child blood sample shall not be stored, retained, and used by the department unless the parent or guardian is fully informed of the benefits of research regarding preventing heritable and congenital disorders and is given a reasonable opportunity to object to the storage, retention, and use of the newborn child blood sample collected.
(e)The genetic disease unit is authorized to make grants or contracts or payments to vendors approved by the department for all of the following:
(1)Testing and counseling services.
(2)Demonstration projects to determine the desirability and feasibility of additional tests or new genetic services.
(3)To initiate the development of genetic services in areas of need.
(4)To purchase or provide genetic services from any sums as are appropriated for this purpose.
(f)The genetic disease unit shall evaluate and prepare recommendations on the implementation of tests for the detection of hereditary and congenital diseases, including, but not limited to, biotinidase deficiency and cystic fibrosis. The genetic disease unit shall also evaluate and prepare recommendations on the availability and effectiveness of preventative followup interventions, including the use of specialized medically necessary dietary products.
It is the intent of the Legislature that funds for the support of the evaluations and recommendations required pursuant to this subdivision, and for the activities authorized pursuant to subdivision (e), shall be provided in the annual Budget Act appropriation from the Genetic Disease Testing Fund.
(g)Health care providers that contract with a prepaid group practice health care service plan that annually has at least 20,000 births among its membership, may provide, without contracting with the department, any or all of the testing and counseling services required to be provided under this section or the regulations adopted pursuant thereto, if the services meet the quality standards and adhere to the regulations established by the department and the plan pays that portion of a fee established under this section that is directly attributable to the departments cost of administering the testing or counseling service and to any required testing or counseling services provided by the state for plan members. The payment by the plan, as provided in this subdivision, shall be deemed to fulfill any obligation the provider or the providers patient may have to the department to pay a fee in connection with the testing or counseling service.
(h)The department may appoint experts in the area of genetic screening, including, but not limited to, cytogenetics, molecular biology, prenatal, specimen collection, and ultrasound to provide expert advice and opinion on the interpretation and enforcement of regulations adopted pursuant to this section. These experts shall be designated agents of the state with respect to their assignments. These experts shall receive no salary, but shall be reimbursed for expenses associated with the purposes of this section. All expenses of the experts for the purposes of this section shall be paid from the Genetic Disease Testing Fund.
(i)A parent or legal guardian of a minor may request the department to destroy, destroy or not use for research purposes, or both, the blood sample of the minor collected as a newborn, and the department shall do so.
(j)An individual who is at least 18 years of age may request the department to destroy, destroy or not use for research purposes, or both, his or her blood sample that was collected, and the department shall do so.
SEC. 2.Section 125003 is added to the Health and Safety Code, to read:125003.(a)The department shall prepare and provide informational materials regarding newborn child blood samples collected pursuant to this article that include, but are not limited to, all of the following:
(1)Storage, retention, and use of the blood sample.
(2)The parent or legal guardians right to request that his or her minor childs blood sample be destroyed, destroyed or not used for research purposes, or both, and the information necessary to make that request.
(3)The right of an individual who is at least 18 years of age to request that his or her blood sample be destroyed, destroyed or not used for research purposes, or both, and the information necessary to make that request.
(b)The department shall provide to a parent or legal guardian the standard informed consent form provided in Section 125004 regarding the options for newborn child screening and retention of newborn child blood samples collected pursuant to this article.
(b)
(c)The informational materials and the standard informed consent form prepared and provided by the department shall be distributed as follows:
(1)Every birth attendant engaged in providing perinatal care shall provide a pregnant woman, prior to the estimated date of delivery, with a copy of the informational materials and a copy of the standard informed consent form provided by the department.
(2)Every perinatal licensed health facility shall provide each pregnant woman admitted for delivery with a copy of the informational materials and a copy of the standard informed consent form provided by the department, prior to collection of the blood sample, if that information or standard informed consent form has not been provided pursuant to paragraph (1).
(3)The local registrar of births shall provide a copy of the informational material and a copy of the standard informed consent form provided by the department to each person registering the birth of a newborn that occurred outside of a perinatal licensed health facility when the newborn was not admitted to a perinatal licensed health facility within the first 30 days of age. The local health officer and the department shall be notified of each of these registrations by the local registrar.
(c)
(d)For the purposes of this section, the following terms shall have the following meanings:
(1)Birth attendant means a person licensed or certified by the state to provide maternity care and to deliver pregnant women or to practice medicine.
(2)Perinatal licensed health facility means a health facility licensed by the state and approved to provide perinatal, delivery, newborn intensive care, newborn nursery, or pediatric services.
SEC. 3.Section 125004 is added to the Health and Safety Code, to read:125004.(a)The department shall prepare a standard informed consent form setting forth clearly and in detail all of the following:
(1)A brief, plain language explanation of, and the purpose for, the newborn child screening test and retention of newborn child blood samples collected pursuant to this article.
(2)A description of the benefits of both early newborn child screening and the associated research undertaken regarding preventable heritable or congenital disorders.
(3)That the parent or legal guardian of the newborn child may consent to the newborn child screening test.
(4)That the parent or legal guardian of the newborn child has the right to refuse a newborn child screening test on the ground that the test conflicts with his or her religious beliefs or practices.
(5)That if the parent or legal guardian of the newborn child refuses to have the newborn child screening test done, he or she accepts all responsibility and liability for the possible consequences.
(6)A description of the health risks associated with foregoing the newborn child screening test.
(7)That the parent or legal guardian of the newborn child may consent to the storage, retention, and use of the blood sample.
(8)That the parent or legal guardian of the newborn child may request the department to destroy or not use for research purposes, or both, the blood sample collected and screened.
(b)A copy of the standard informed consent form shall be maintained with the newborn childs medical records.
(a)It is the policy of the State of California to make every effort to detect, as early as possible, phenylketonuria and other preventable heritable or congenital disorders leading to intellectual disability or physical defects.
The department shall establish a genetic disease unit, that shall coordinate all programs of the department in the area of genetic disease. The unit shall promote a statewide program of information, testing, and counseling services and shall have the responsibility of designating tests and regulations to be used in executing this program.
The information, tests, and counseling for children shall be in accordance with accepted medical practices and shall be administered to each child born in California once the department has established appropriate regulations and testing methods. The information, tests, and counseling for pregnant women shall be in accordance with accepted medical practices and shall be offered to each pregnant woman in California once the department has established appropriate regulations and testing methods. These regulations shall follow the standards and principles specified in Section 124980. The department may provide laboratory testing facilities or contract with any laboratory that it deems qualified to conduct tests required under this section. However, notwithstanding former Section 125005, provision of laboratory testing facilities by the department shall be contingent upon the provision of funding therefor by specific appropriation to the Genetic Disease Testing Fund enacted by the Legislature. If moneys appropriated for purposes of this section are not authorized for expenditure to provide laboratory facilities, the department may nevertheless contract to provide laboratory testing services pursuant to this section and shall perform laboratory services, including, but not limited to, quality control, confirmatory, and emergency testing, necessary to ensure the objectives of this program.
(b)The department shall charge a fee for any tests performed pursuant to this section. The amount of the fee shall be established and periodically adjusted by the director in order to meet the costs of this section.
(c)The department shall inform all hospitals or physicians and surgeons, or both, of required regulations and tests and may alter or withdraw any of these requirements whenever sound medical practice so indicates. To the extent practicable, the department shall provide notice to hospitals and other payers in advance of an increase in the fees charged for the program.
(d)This section shall not apply if a parent or guardian of the newborn child objects to a test on the ground that the test conflicts with his or her religious beliefs or practices.
(e)The genetic disease unit is authorized to make grants or contracts or payments to vendors approved by the department for all of the following:
(1)Testing and counseling services.
(2)Demonstration projects to determine the desirability and feasibility of additional tests or new genetic services.
(3)To initiate the development of genetic services in areas of need.
(4)To purchase or provide genetic services from any sums as are appropriated for this purpose.
(f)The genetic disease unit shall evaluate and prepare recommendations on the implementation of tests for the detection of hereditary and congenital diseases, including, but not limited to, biotinidase deficiency and cystic fibrosis. The genetic disease unit shall also evaluate and prepare recommendations on the availability and effectiveness of preventative followup interventions, including the use of specialized medically necessary dietary products.
It is the intent of the Legislature that funds for the support of the evaluations and recommendations required pursuant to this subdivision, and for the activities authorized pursuant to subdivision (e), shall be provided in the annual Budget Act appropriation from the Genetic Disease Testing Fund.
(g)Health care providers that contract with a prepaid group practice health care service plan that annually has at least 20,000 births among its membership, may provide, without contracting with the department, any or all of the testing and counseling services required to be provided under this section or the regulations adopted pursuant thereto, if the services meet the quality standards and adhere to the regulations established by the department and the plan pays that portion of a fee established under this section that is directly attributable to the departments cost of administering the testing or counseling service and to any required testing or counseling services provided by the state for plan members. The payment by the plan, as provided in this subdivision, shall be deemed to fulfill any obligation the provider or the providers patient may have to the department to pay a fee in connection with the testing or counseling service.
(h)The department may appoint experts in the area of genetic screening, including, but not limited to, cytogenetics, molecular biology, prenatal, specimen collection, and ultrasound to provide expert advice and opinion on the interpretation and enforcement of regulations adopted pursuant to this section. These experts shall be designated agents of the state with respect to their assignments. These experts shall receive no salary, but shall be reimbursed for expenses associated with the purposes of this section. All expenses of the experts for the purposes of this section shall be paid from the Genetic Disease Testing Fund.
(i)A parent or legal guardian of a minor may request the department to destroy, not use for research purposes, or both, the blood sample of the minor collected as a newborn, and the department shall do so.
(j)An individual who is at least 18 years of age may request the department to destroy, not use for research purposes, or both, his or her blood sample that was collected, and the department shall do so.
SEC. 2.Section 125003 is added to the Health and Safety Code, to read:125003.(a)The department shall prepare and provide informational materials regarding newborn child blood samples collected pursuant to this article that include, but are not limited to, all of the following:
(1)Storage, retention, and use of the blood sample.
(2)The parent or legal guardians right to request that his or her minor childs blood sample be destroyed, not used for research purposes, or both, and the information necessary to make that request.
(3)The right of an individual who is at least 18 years of age to request that his or her blood sample be destroyed, not used for research purposes, or both, and the information necessary to make that request.
(b)The informational materials prepared and provided by the department shall be distributed as follows:
(1)Every birth attendant engaged in providing perinatal care shall provide a pregnant woman, prior to the estimated date of delivery, with a copy of the informational materials provided by the department.
(2)Every perinatal licensed health facility shall provide each pregnant woman admitted for delivery with a copy of the informational materials provided by the department, prior to collection of the blood sample, if that information has not been provided pursuant to paragraph (1).
(3)The local registrar of births shall provide a copy of the informational material provided by the department to each person registering the birth of a newborn that occurred outside of a perinatal licensed health facility when the newborn was not admitted to a perinatal licensed health facility within the first 30 days of age. The local health officer and the department shall be notified of each of these registrations by the local registrar.
(c)For the purposes of this section, the following terms shall have the following meanings:
(1)Birth attendant means a person licensed or certified by the state to provide maternity care and to deliver pregnant women or to practice medicine.
(2)Perinatal licensed health facility means a health facility licensed by the state and approved to provide perinatal, delivery, newborn intensive care, newborn nursery, or pediatric services.
|
Date
|
Status
|
|---|---|
| Jul 8, 2015 | From committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on HEALTH. |
| Jun 18, 2015 | Referred to Com. on HEALTH. |
| Jun 3, 2015 | Read third time. Passed. Ordered to the Senate. (Ayes 66. Noes 11. Page 1854.) |
| Jun 3, 2015 | In Senate. Read first time. To Com. on RLS. for assignment. |
| Jun 3, 2015 | Read third time. Passed. Ordered to the Senate. |
| Jun 1, 2015 | Read second time. Ordered to third reading. |
| May 28, 2015 | Read second time and amended. Ordered returned to second reading. |
| May 28, 2015 | From committee: Amend, and do pass as amended. (Ayes 17. Noes 0.) (May 28). |
| May 13, 2015 | In committee: Set, first hearing. Referred to APPR. suspense file. |
| May 4, 2015 | Re-referred to Com. on APPR. |
| Apr 30, 2015 | Read second time and amended. |
| Apr 29, 2015 | From committee: Amend, and do pass as amended and re-refer to Com. on APPR. (Ayes 17. Noes 0.) (April 28). |
| Apr 22, 2015 | Re-referred to Com. on HEALTH. |
| Apr 21, 2015 | From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended. |
| Apr 14, 2015 | In committee: Hearing postponed by committee. |
| Mar 26, 2015 | Re-referred to Com. on HEALTH. |
| Mar 25, 2015 | Read second time and amended. |
| Mar 24, 2015 | From committee: Amend, and do pass as amended and re-refer to Com. on HEALTH. (Ayes 9. Noes 2.) (March 17). |
| Mar 12, 2015 | Re-referred to Com. on P. & C.P. |
| Mar 11, 2015 | From committee chair, with author's amendments: Amend, and re-refer to Com. on P. & C.P. Read second time and amended. |
| Feb 2, 2015 | Referred to Coms. on P. & C.P. and HEALTH. |
| Jan 23, 2015 | From printer. May be heard in committee February 22. |
| Jan 22, 2015 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Jun 3, 2015 | AB 170 GATTO Assembly Third Reading | Assembly Floor |
Passed |
|
| May 28, 2015 | Do pass as amended. | Assembly Standing Committee on Appropriations |
Passed |
|
| Apr 28, 2015 | Do pass as amended and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Health |
Passed |
|
| Mar 17, 2015 | Do pass as amended and be re-referred to the Committee on [Health] | Assembly Standing Committee on Privacy and Consumer Protection |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
AB 170 (Gatto) Page 6 of 6
SENATE COMMITTEE ON HEALTH
Senator Ed Hernandez, O.D., Chair
BILL NO: AB 170
AUTHOR: |
Gatto |
||
VERSION: |
July 8, 2015 |
||
HEARING DATE: |
July 15, 2015 |
|
|
CONSULTANT: |
Reyes Diaz |
||
SUBJECT: Newborn screening: genetic diseases: blood samples collected.
SUMMARY:
Requires the Department of Public Health to provide information about genetic testing and to obtain a signed form, as specified, from a parent or guardian of a newborn child regarding the collection of blood samples, as specified. Allows parents and guardians, and individuals at least 18 years of age, to request, as specified, that blood samples not be used for medical research, or to be destroyed, or both, as specified.
Existing law:
Requires the Department of Public Health (DPH) to establish a genetic disease unit to coordinate all DPH programs in the area of genetic disease that will promote a statewide program of information, testing, and counseling services and to have the responsibility of designating tests and regulations to be used in executing this program and to have the responsibility of designating tests and regulations to be used in executing the California Newborn Screening Program (CNSP).
Requires DPH to provide genetic screening and follow-up services. Allows DPH to provide laboratory (lab) testing facilities or work with qualified outside labs to conduct testing.
Requires DPH to charge a fee for newborn screening and follow-up services, and requires the amount of the fee to be periodically adjusted in order to meet the costs of the CNSP.
Requires DPH to evaluate and prepare recommendations on the implementation of tests for the detection of hereditary and congenital diseases, including, but not limited to, biotinidase deficiency and cystic fibrosis. Requires DPH to also evaluate and prepare recommendations on the availability and effectiveness of preventative follow-up interventions, including the use of specialized medically necessary dietary products.
Requires statewide screening of newborns to include tandem mass spectrometry screening for fatty acid oxidation, amino acid, and organic acid disorders and congenital adrenal hyperplasia, and to include screening for severe combined immunodeficiency, as soon as possible.
Requires specified entities to provide parents and guardians information about the genetic screening program and blood spot collection, including one’s right to opt out, prior to the estimated date of delivery or at the pregnancy clinic prior to birth and collection of the blood sample.
Allows for parents and guardians to decline genetic testing and to request a child’s blood spot not be used for research purposes or to be destroyed by the lab if the request it submitted in writing, as specified.
This bill:
Requires DPH to provide information about genetic disease tests and to obtain a signed informational acknowledgement form for the receipt of information by the parent or guardian of a newborn child regarding the storage, retention, and use of the newborn child’s blood sample for medical research.
Requires DPH to prepare informational material, confined to a single page, that provides information regarding the newborn blood sample collection to include, but not be limited to:
A brief, plain language explanation of, and the purpose for, the newborn child screening test and the storage, retention, and use of newborn child blood samples;
A description of the benefits of both early newborn child screening and the associated research undertaken regarding preventable heritable or congenital disorders;
A description of the California Biobank Program (CBP), specifically pertaining to the Genetic Disease Screening Program (GDSP), and subsequent storage, retention, and use of the blood sample for medical research; and,
An explanation of the parent’s or legal guardian’s right, and a statement of an individual at least 18 years of age having the right, to request that the blood sample be destroyed or not used for research purposes, or both, and the information necessary to make that request.
Requires DPH to prepare a standard informational acceptance form, confined to a single page and presented on a separate document from the informational material required in 2) above, that includes the following:
A brief, plan language explanation of, and the purpose for, the newborn child screening test and retention of blood samples collected;
An explanation of the parent’s or legal guardian’s right to request that a child’s blood sample be destroyed or not used for research purposes, or both, and the information necessary to make that request;
A space for the parent or legal guardian to acknowledge receipt of informational materials regarding the storage, retention, and use of the blood sample for medical research; and,
A space for the parent or legal guardian to sign and date the form.
Requires DPH to distribute to a parent or legal guardian the two separate informational materials, each confined to one page, as follows:
A birth attendant engaged in providing prenatal care is required to provide a pregnant woman, prior to the estimated delivery date, with a copy of both required materials;
If not provided as required in a) above, a perinatal licensed health facility is required to provide each pregnant woman admitted for delivery with both required materials; and,
The local registrar of births and deaths is required to provide both required materials to each person registering the birth of a newborn that occurred outside of a perinatal licensed health facility when the newborn was not admitted to a perinatal licensed facility within the first 30 days of age. Requires the local registrar to notify the local health officer and DPH of each of these types of registrations.
Requires the acceptance form to be maintained in the medical record of the mother of the newborn child.
Specifies that if there is no signed standard informational acceptance form in the mother’s medical record, the newborn child will be administered the genetic screening test and the blood sample will be stored and retained for medical research.
Allows a parent or legal guardian of a minor, or an individual who is at least 18 years of age, to request that DPH destroy the blood sample of the minor or of the individual collected as a newborn, or not use it for research purposes, or both. Requires DPH to comply with the requests.
Requires, if a parent or legal guardian or individual at least 18 years of age provides his or her email address, DPH to send an email acknowledging receipt of the request.
FISCAL EFFECT:
According to the Assembly Appropriations Committee:
One-time costs of $120,000 to promulgate regulations (Genetic Disease Testing Fund).
Annual costs of $550,000 (Genetic Disease Testing Fund) for printing, storage, and distribution of forms, and staff to provide technical support and enforce collection and submittal of forms. If an increased number of requests to destroy specimens is received, minor potential increased laboratory staff costs would be incurred.
PRIOR VOTES:
Assembly Floor: |
66 - 11 |
Assembly Appropriations Committee: |
17 - 0 |
Assembly Health Committee: Assembly Privacy and Consumer Protection Committee: |
17 - 0
9 - 2 |
COMMENTS:
Author’s statement. According to the author, newborn screening is one of the great public health success stories in this country, but what happens to the samples after the screening process is completed raises serious and troubling questions of consent and privacy. In the case of California and a handful of other states, these samples are indefinitely stored in state repositories and made available to researchers for a fee. Most parents are poorly informed, if at all, about the storage and medical research of these samples. Nevertheless, parents are assumed to have consented to long-term storage and third-party use of their child’s biological sample unless they explicitly refuse in writing. California must revise its approach to long-term storage and use of newborn DNA samples, and include parents in the decision-making process. It is imperative for both the health of this program and Californians’ continued trust in their government that parents be fully informed of the CBP and the intended future use of their child’s DNA. AB 170 will ensure that parents have the right to protect their children’s genetic privacy. Parents, understandably, want to be actively involved in decision-making regarding their children’s personal health information. That choice is currently being denied.
CNSP. In 1966, California began its CNSP with the testing of phenylketonuria. Since its creation, the CNSP has been expanded several times as new discoveries are made and tests developed, and now screens for more than 70 disorders. Diseases have been continually added through regulation and legislation.
Prior to leaving the hospital, a
few drops of blood from a newborn’s heel are collected on filter
paper. The newborn screening test should be done when the baby is at
least 12 hours of age but before six days of age. The ideal time to
do the test is when the baby is between 24 and 48 hours of age. Blood
collected before 12 hours of age is not always reliable for some
metabolic diseases. The sample is sent to one of eight regional labs
that contract with DPH for testing. The results are sent to DPH for
data collection and quality control. Parents obtain the test results
from the baby’s doctor or clinic. It takes about two weeks for the
doctor to receive the written results. If the baby needs more tests,
parents get a letter or a phone call a few days after discharge from
the hospital. Positive test results are immediately telephoned to a
follow-up coordinator at one of the Newborn Screening Area Service
Centers throughout the state. The coordinator contacts the newborn’s
physician to arrange for repeat testing. If repeat testing determines
that the baby has a disorder, the coordinator will supply the latest
clinical information on diagnosis and treatment and assist with
referrals to special care. In 2009-10, approximately 520,000 newborns
were screened for 75 genetic disorders. Approximately 9,200, or under
2%, were classified as positive or questionable and were referred for
follow-up testing or services.
Current
regulations permit a parent to decline the test. A parent must then
sign a special form that states that not having the test done can
result in serious illness or permanent damage to their child. It also
states that the parent must accept responsibility should this occur.
CBP. The CBP, a large and diverse biobank maintained by DPH, houses over 17.5 million prenatal serum samples and newborn leftover blood spots. These samples were collected for testing by the Prenatal and Screening Program and CNSP, which are linked to GDSP data and California Birth Defects Monitoring Program (CBDMP) registry data. The samples and data are also linked to the State Registrar of Vital Statistics databases that include fetal death, live birth, and death data.
According to DPH, information is currently given to pregnant women in DPH’s booklet, Important Information for Parents about the Newborn Screening Test, which is available in English, Spanish, Armenian, Cambodian, Chinese, Farsi, Hmong, Korean, Laotian, Russian, Tagalog, and Vietnamese. The booklet is required to be provided to women, free of charge, prior to the estimated date of delivery or at the maternal hospital where she is going to give birth. The booklet, which is about 15 pages long, provides an address for parents to request that GDSP not use a child’s blood spot for research purposes and/or to be destroyed by the lab.
Prior legislation. AB 1559 (Pan, Chapter 565, Statutes of 2014), expands DPH statewide screening of newborns to include screening for adrenoleukodystrophy (ALD) as soon the federal Recommended Uniform Screening Panel approve the addition of ALD.
SB 222 (Padilla), of 2014, would have enacted the Genetic Information Privacy Act, which would have required an individual’s written authorization prior to the collection of genetic information for testing, analysis, retention, or disclosure. SB 222 was held in the Senate Appropriations Committee.
SB 1267 (Padilla), of 2012, would have required an individual’s written authorization prior to the collection of genetic information for testing, analysis, retention or disclosure. Would have required destruction of the genetic information upon completion of the purpose authorization was obtained. SB 1267 was held in the Senate Appropriations Committee.
AB 395 (Pan, Chapter 461, Statutes of 201), expands statewide screening of newborns to include screening for severe combined immunodeficiency.
SB 1103 (Committee on Budget and Fiscal Review, Chapter 228, Statutes of 2004), expands statewide screening of newborns to include tandem mass spectrometry screening for fatty acid oxidation, amino acid, organic acid disorders, and congenital adrenal hyperplasia.
SB 537 (Greene, Chapter 1011, Statutes of 1998), required DPH to establish a program to provide extended newborn genetic screening services for persons who elect to have, and pay for, the additional screening.
Support. Supporters of this bill argue that parents should have a truly informed choice about whether the state should permanently retain and use their child’s personal genetic information. Supporters state that newborn screening itself is an important public health program but that there are troubling consent and privacy issues raised by the storage and use of samples long after the screening process has concluded. Supporters further argue that studies have shown that parents want to be actively involved in the decision making regarding their child’s personal health information and whether the state should maintain a sample after screening is complete.
Opposition. The California Hospital Association (CHA) argues that this bill requires obstetricians and hospitals to give pregnant women four handouts related to genetic screening and blood spot collection instead of the currently required two handouts. CHA states that revising the process for genetic screening this year is premature as the federal government is currently developing new requirements regarding consent for blood spot research. CHA argues that it is inevitable that some health personnel and some parents will confuse the “opt-out” process of the GDSP with DPH’s current process to opt-out of screening the baby for genetic diseases, which could result in more seriously and permanently disabled babies, and deaths.
Policy comment. DPH requires specified entities to provide parents and guardians information about the GDSP and blood spot collection (including one’s right to have a child’s blood spot not used for medical research or to have it destroyed) prior to the estimated date of delivery or at the pregnancy clinic prior to birth and collection of the blood sample. The author has stated that the intent of this bill is to provide clearer information to women during a hectic time. However, nothing in this bill ensures that providing an additional two forms to women, in addition to other required forms, would actually more effectively inform them about the GDSP and blood spot collection. In the opinion of staff, the need for this bill is unclear.
SUPPORT AND OPPOSITION:
Support: American Federation of State, County and Municipal Employees, AFL-CIO
Council for Responsible Genetics
Oppose: California Hospital Association
-- END –
AB 170
Page 3
ASSEMBLY THIRD READING
AB 170
(Gatto)
As Amended May 28, 2015
Majority vote
Committee |
Votes |
Ayes |
Noes |
Privacy |
9-2 |
Gatto, Wilk, Calderon, Chau, Cooper, Dababneh, Dahle, Gordon, Low |
Baker, Chang |
Health |
17-0 |
Bonta, Maienschein, Bonilla, Burke, Chávez, Chiu, Gomez, Gonzalez, Roger Hernández, Lackey, Ridley-Thomas, Rodriguez, Santiago, Steinorth, Thurmond, Waldron, Wood |
|
Appropriations |
17-0 |
Gomez, Bigelow, Bonta, Calderon, Chang, Daly, Eggman, Gallagher, Eduardo Garcia, Gordon, Holden, Jones, Quirk, Rendon, Wagner, Weber, Wood |
|
SUMMARY:
Requires the Department of Public Health (DPH) to provide information to the parent or guardian of a newborn child about the California Newborn Screening Program (CNSP) and obtain a signed acknowledgment form regarding the storage, retention, and use of the newborn child’s blood sample for medical research, and also allows a parent or legal guardian of a minor or an individual who is at least 18 years of age to request that the blood sample be destroyed or not used for research purposes. Specifically, this bill:
Requires DPH to provide information about the CNSP and obtain a signed acknowledgment form from the parent or guardian of a newborn child regarding the storage, retention, and use of the newborn child's blood sample for medical research.
Clarifies that the fee charged by DPH for any tests shall be established and adjusted to meet the reasonable costs of the program.
Authorizes a parent or legal guardian of a minor, or an individual who is at least 18 years of age, to request that DPH destroy the blood sample of the minor collected as a newborn, or not use it for research purposes, or both, and requires DPH to comply with that request.
Requires DPH to provide informational materials regarding newborn child blood samples that include, but are not limited to, all of the following information:
A brief, plain language explanation of, and the purpose for, the newborn child screening test and the storage, retention and use of newborn child blood samples collected pursuant to the CNSP;
A description of the benefits of early newborn child screening and the associated research undertaken regarding preventable heritable or congenital disorders;
A description of the California Biobank Program, specifically as it pertains to the Genetic Disease Screening Program, and the subsequent storage, retention, and use of the newborn child's blood sample for medical research; and,
An explanation of the parent's or legal guardian's right to request that his or her minor child's blood samples be destroyed or not used for research purposes, or both, and the information necessary to make that request.
A statement that an individual who is at least 18 years of age has the right to request that his or her blood sample be destroyed or not used for research purposes, or both, and the information necessary to make that request.
Requires these informational materials to be confined to a single page and presented in a document separate from the standard informational acceptance form, as specified.
Requires DPH to prepare a standard informational acceptance form that includes all of the following:
A brief, plain language explanation of the newborn child screening test and retention of newborn child blood samples collected pursuant to the CNSP.
An explanation of the parent's or legal guardian's right to request that his or her minor child's blood sample be destroyed or not used for research purposes, or both, and the information necessary to make that request;
A space for the parent or legal guardian of the newborn child to acknowledge receipt of informational materials; and,
A space for the parent or legal guardian of the newborn child to sign and date the form
Requires the standard informational acceptance form to be confined to a single page and presented in a separate document from the informational materials.
Requires a copy of the standard informational acceptance form to be maintained in the medical record of the mother of the newborn child.
Requires, in the event that there is no signed standard informational acceptance form retained in the mother's medical record, the newborn child to receive the genetic screening test and the newborn child blood sample to be stored and retained for medical research, as specified.
Requires DPH generally to provide a parent or legal guardian with the informational materials and standard informational acceptance form regarding the retention of newborn child blood samples.
Requires the informational materials and standard informational acceptance form to be distributed as follows:
A birth attendant who provides perinatal care to a pregnant woman, prior to the estimated date of delivery, shall provide a copy of the informational materials and a copy of the standard informational acceptance form provided by DPH.
If the informational material or standard informational acceptance form has not yet been provided, a perinatal licensed health facility shall provide a pregnant woman admitted for delivery with a copy of the informational materials and a copy of the standard informational acceptance form provided by DPH.
The local registrar of births and deaths shall provide a copy of the informational material and a copy of the standard informational acceptance form provided by DPH to each person registering the birth of a newborn that occurred outside of a perinatal licensed health facility when the newborn was not admitted to a perinatal licensed health facility within the first 30 days of age; and shall notify the local health officer and DPH of each of these registrations.
Makes findings and declarations pertaining to legislative intent.
Makes other clarifying or nonsubstantive changes.
FISCAL EFFECT: According to the Assembly Appropriations Committee:
One-time costs of $120,000 to promulgate regulations (Genetic Disease Testing Fund).
Annual costs of $550,000 (Genetic Disease Testing Fund) for printing, storage, and distribution of forms, and staff to provide technical support and enforce collection and submittal of forms. If an increased number of requests to destroy specimens is received, minor potential increased laboratory staff costs would be incurred.
COMMENTS:
Purpose of this bill. This bill is intended to ensure the informed consent of parents and protect the genetic privacy of children born in this state by requiring DPH to provide parents with informational materials and a written acknowledgment form regarding the CNSP, its use of blood samples for subsequent medical research, and the right to request that the blood sample for one's child or oneself be destroyed or not used for research purposes. This measure is author-sponsored.
Analysis Prepared by: Jennie Bretschneider / P. & C.P. / (916) 319-2200 FN: 0000826
AB 170
Page 2
Date of Hearing: May 13, 2015
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Jimmy Gomez, Chair
AB 170
(Gatto) – As Amended April 30, 2015
Policy Committee: |
Privacy and Consumer Protection |
Vote: |
9 - 2 |
|
Health |
|
17 - 0 |
|
|
|
|
Urgency: No State Mandated Local Program: Yes Reimbursable: Yes
SUMMARY:
This bill changes requirements related to the state's newborn screening program to provide additional information about the storage and use of newborn screening blood samples for research. Specifically, this bill:
Requires the California Department of Public Health (CDPH) to provide information about the newborn screening tests, and to obtain a signed informational acknowledgment form for the receipt of specified information by the parent or guardian of a newborn child regarding the storage, retention, and use of the newborn child’s blood sample for medical research.
Modifies provisions related to the newborn screening program fee, to allow the fee to be adjusted to meet the reasonable costs of the program.
Allows people to request their blood samples, or those of their children, be destroyed or not used for research, and requires CDPH to comply with those requests.
Requires CDPH to prepare, provide, and distribute a single page of specified informational materials, and a standard informational acceptance form.
Requires every birth attendant and every perinatal licensed health facility to provide each pregnant woman a copy of the informational materials and a copy of the standard informational acceptance form, and requires the local registrar of births to provide this information for births outside licensed facilities.
Requires a copy of the standard informational acceptance form to be maintained with the medical records of the mother of the newborn child.
FISCAL EFFECT:
One-time costs of $120,000 to promulgate regulations (Genetic Disease Testing Fund).
Annual costs of $550,000 (Genetic Disease Testing Fund) for printing, storage, and distribution of forms, and staff to provide technical support and enforce collection and submittal of forms. If an increased number of requests to destroy specimens is received, minor potential increased laboratory staff costs would be incurred.
COMMENTS:
Purpose. According to the author, newborn screening is one of the great public health success stories in this country, but what happens to the samples after the screening process is completed raises serious and troubling questions of consent and privacy. In the case of California and a handful of other states, these samples are indefinitely stored in state repositories and research is conducted using the samples. The author states that most parents are poorly informed, if at all, about the storage and medical research of these samples.
Genetic Disease Screening Program. In 1966, California began its newborn screening program with the testing of phenylketonuria. Since its creation, the program has been expanded several times as new discoveries are made and tests developed, and now screens for more than 70 disorders. Diseases have been continually added through regulation and legislation.
Current regulations permit a parent to decline the screening test. A parent must then sign a form that states that not having the test done can result in serious illness or permanent damage to their child. It also states that the parent must accept responsibility should this occur.
California BioBank. DPH maintains a large and diverse biobank, the California Biobank Program, which houses over 17.5 million prenatal serum samples and newborn leftover blood spots. These samples were collected for testing by the prenatal and newborn screening programs. The program is an internationally recognized public health asset because of its large size and culturally, geographically and genetically diverse population. Current CDPH regulations allow parents to request their child's specimen be destroyed or not used for research; however, the option to opt out does not appear to be particularly well-publicized
Support. The American Federation of State, County and Municipal Employees and the Council for Responsible Genetics support this bill.
Opposition. There was significant opposition to prior versions of this bill that had more impact on the newborn screening program. The bill has been significantly amended to address only increased information related to the storage of blood spots and their use in research. According to the author, all opposition except for the California Hospital Association has submitted letters that they are neutral on the current version.
Staff Comments. This bill includes duplicative requirements related to the production and distribution of information and forms. Numerous provisions could be streamlined and clarified. Additionally, staff notes there is a significant administrative burden to obtain signed informational acknowledgement forms related to approximately 500,000 births annually. It is unclear whether the collection of forms is unclear whether these additional administrative costs will result in a tangible benefit.
Analysis Prepared by: Lisa Murawski / APPR. / (916) 319-2081
AB 170
Page 8
Date of Hearing: April 28, 2015
ASSEMBLY COMMITTEE ON HEALTH
Rob Bonta, Chair
AB 170
Gatto – As Amended April 21, 2015
SUBJECT: Newborn screening: genetic diseases: blood samples collected.
SUMMARY: Requires Department of Public Health (DPH) to provide information about the genetic disease screening tests and obtain a signed informational acknowledgment form for the receipt of information by the parent or guardian of a newborn child regarding the storage, retention, and use of the newborn child’s blood sample for medical research. Specifically, this bill:
Permits a parent or legal guardian of a minor, or an individual who is at least 18 years of age, to request that DPH destroy the blood sample of the minor collected as a newborn, or not use it for research purposes, or both.
Requires DPH to comply with any requests to destroy the blood sample of the minor collected as a newborn, or not use it for research purposes, or both.
Requires DPH to prepare and provide informational materials regarding newborn child blood samples collected that include, but are not limited to, all of the following:
Storage, retention, and use of the blood sample;
The parent or legal guardian’s right to request that his or her minor child’s blood sample be destroyed or not used for research purposes, or both, and the information necessary to make that request; and,
The right of an individual who is at least 18 years of age to request that his or her blood sample be destroyed or not used for research purposes, or both, and the information necessary to make that request.
Requires informational materials to be confined to a single page and presented in a separate document from informational materials pertaining to the newborn screening program.
Requires the informational materials and the standard informational acceptance form prepared to be distributed as follows:
Requires maternity care providers to provide a pregnant woman, prior to the estimated date of delivery, with a copy of the informational materials and a copy of the standard informational acceptance form provided by DPH.
Requires every perinatal licensed health facility to provide each pregnant woman admitted for delivery with a copy of the informational materials and a copy of the standard informational acceptance form provided by DPH, prior to collection of the blood sample, if that information or standard informational acceptance form was not provided at the perinatal care visit.
Requires DPH to provide to a parent or legal guardian a standard informational acceptance form regarding the options for newborn child screening and retention of newborn child blood samples collected. The standard informational acceptance form must include all of the following:
A brief, plain language explanation of, and the purpose for, the newborn child screening test and retention of newborn child blood samples collected pursuant to this article;
A description of the benefits of both early newborn child screening and the associated research undertaken regarding preventable heritable or congenital disorders;
A description of the California Biobank Program, specifically as it pertains to the Genetic Disease Screening Program, and subsequent storage, retention, and use of the newborn child’s blood sample for medical research;
A space for the parent or legal guardian of the newborn child to acknowledge receipt of informational materials regarding the newborn child screening test, and the storage, retention, and use of the newborn child’s blood sample for medical research; and,
A space for the parent or legal guardian of the newborn child to sign and date the form.
Requires a copy of the standard informational acceptance form to be maintained with the newborn child’s medical records.
EXISTING LAW:
Requires DPH to establish a genetic disease unit to coordinate all DPH programs in the area of genetic disease that will promote a statewide program of information, testing, and counseling services and to have the responsibility of designating tests and regulations to be used in executing this program and to have the responsibility of designating tests and regulations to be used in executing the California Newborn Screening Program (CNSP).
Requires DPH to provide genetic screening and follow-up services. Allows DPH to provide laboratory (lab) testing facilities or work with qualified outside labs to conduct testing.
Requires DPH to charge a fee for newborn screening and follow-up services, and requires the amount of the fee to be periodically adjusted in order to meet the costs of CNSP.
Requires DPH to evaluate and prepare recommendations on the implementation of tests for the detection of hereditary and congenital diseases, including, but not limited to, biotinidase deficiency and cystic fibrosis. Requires DPH to also evaluate and prepare recommendations on the availability and effectiveness of preventative follow-up interventions, including the use of specialized medically necessary dietary products.
Requires statewide screening of newborns to include tandem mass spectrometry screening for fatty acid oxidation, amino acid, and organic acid disorders and congenital adrenal hyperplasia, and to include screening for severe combined immunodeficiency, as soon as possible.
FISCAL EFFECT: This bill has not yet been analyzed by a fiscal committee.
COMMENTS:
PURPOSE OF THIS BILL. According to the author, newborn screening is one of the great public health success stories in this country, but what happens to the samples after the screening process is completed raises serious and troubling questions of consent and privacy. In the case of California and a handful of other states, these samples are indefinitely stored in state repositories and made available to researchers for a fee. The author states that most parents are poorly informed, if at all, about the storage and medical research of these samples.
The author argues that parents are assumed to have consented to long-term storage and third-party use of their child's biological sample unless they explicitly refuse in writing. California must revise its approach to long-term storage and use of newborn Deoxyribonucleic acid (DNA) samples, and include parents in the decision-making process. It is imperative for both the health of this program and Californians' continued trust in their government that parents be fully informed of the Biobank program and the intended future use of their child's DNA.
The author concludes that this bill will ensure that parents have the right to protect their children's genetic privacy. Parents, understandably, want to be actively involved in decision-making regarding their children's personal health information. That choice is currently being denied.
BACKGROUND. In 1966 California began its CNSP with the testing of phenylketonuria. Since its creation, the CNSP has been expanded several times as new discoveries are made and tests developed and now screens for more than 70 disorders. Diseases have been continually added through regulation and legislation.
CNSP. Prior to leaving the hospital, a few drops of blood from the newborn’s heel are collected on filter paper. The newborn screening test should be done when the baby is at least 12 hours of age but before six days of age. The ideal time to do the test is when the baby is between 24 and 48 hours of age. Blood collected before 12 hours of age is not always reliable for some metabolic diseases. The sample is sent to one of eight regional labs that contract with the DPH for testing. The results are sent to DPH for data collection and quality control. Parents obtain the test results from the baby’s doctor or clinic. It takes about two weeks for the doctor to receive the written results. If the baby needs more tests, parents get a letter or a phone call a few days after discharge from the hospital. Positive test results are immediately telephoned to a follow-up coordinator at one of the Newborn Screening Area Service Centers throughout the state. The coordinator contacts the newborn’s physician to arrange for repeat testing. If repeat testing determines that the baby has a disorder, the coordinator will supply the latest clinical information on diagnosis and treatment and assist with referrals to special care. In 2009-10, approximately 520,000 newborns were screened for 75 genetic disorders. Approximately 9,200 or under 2% were classified as positive or questionable and were referred for follow-up testing or services.
Disorders screened for by the CNSP have varying degrees of severity. If identified early many of these conditions can be treated before they cause serious health problems. Treatments may include medication, dietary supplements, avoidance of fasting and/or special diet and comprehensive care to reduce morbidity and mortality. This test screens for specific diseases in the following groups:
Metabolic: chemical reactions in the body to create energy and build tissue;
Endocrine: hormones that affect body functions;
Hemoglobin: red blood cells that carry oxygen;
Other genetic diseases;
Cystic Fibrosis; and,
Severe Combined Immunodeficiency.
CNSP disorders cause delays in development, neurological damage,
dehydration, incorrect sex assignment, mental retardation, and death
if not treated at an early newborn age. In California about one out
of every 600 babies tested will have one of these conditions or
diseases.
Current regulations permit a parent to decline the test. A parent
must then sign a special form that states that not having the test
done can result in serious illness or permanent damage to their
child. It also states that the parent must accept responsibility
should this occur.
California BioBank. DPH maintains a large and diverse biobank, the California Biobank Program, which houses over 17.5 million prenatal serum samples and newborn leftover blood spots. These samples were collected for testing by the Prenatal and Screening Program and CNSP that are administered by the Genetic Disease Screening Program (GDSP) and are linked to GDSP data and California Birth Defects Monitoring Program (CBDMP) registry data. The samples and data are also linked to the State Registrar of Vital Statistics databases that include fetal death, live birth and death data. The California Biobank Program (CBP) is an internationally recognized public health asset because of its large size and culturally, geographically and genetically diverse population. The CBP is unique in that no other state or international effort approaches its scale in terms of the number and quality of specimens collected and preserved annually, the number of historic specimens, and existing linkage with statewide prenatal and newborn screening program data, birth defects data, CBDMP data and other population databases.
SUPPORT. The Council for Responsible Genetics (CRG) states in support of the bill that it will assist parents in California in making a truly informed choice about whether the state of California shall permanently retain and use their children’s personal genetic information. Before they are even a week old, 98% of the 4.3 million babies born annually in the United States have a small sample of blood taken from their heels. These newborn bloodspots (NBS) are then screened for a variety of inherited conditions and are often later stored in state-operated databases. Newborn screening itself is an important public health program, but while there are concrete benefits of newborn testing there are also troubling consent and privacy issues raised by the storage and use of the samples long after the screening process has concluded. CRG states that with respect to sample storage and use, there is little transparency regarding storage procedures or the use of the samples after they have been screened. CRG argues not only do most parents never realize they have “consented” to storage of their children’s biological material, they fail to understand that the actual state government (as opposed to the hospital) is the entity in possession of this sample.
CRG argues that several studies have shown that the vast majority of parents want to be actively involved in decision making regarding their children’s personal health information, want the choice as to whether the state should maintain their child’s sample after screening is completed and most oppose the indefinite storage and use of such samples without consent. Even though parents want informed consent to store and use the samples, many states including California do not have clearly articulated policies about consent for the storage and use of samples, do not effectively communicate these policies to parents and do not offer parents a truly informed choice about whether to participate in storage and subsequent use procedures, including human subject research.
CRG further states that the concern of parents that states retain their children’s biological information is heightened because storage procedures and security at these state facilities are arcane and there are laws that truly protect the privacy of genetic information. Californians are enthusiastic about the promise of genetic medicine; but are understandably fearful about how this powerful information can be abused. The sheer amount of genetic data being generated today, and its commercialization, raises serious medical privacy concerns. Many individuals are legitimately concerned that their genetic information will be used against them and are unwilling to participate in medical research or be tested clinically, even when they are at risk for serious disease. CRG concludes that the government has not classified the collection and use of NBS data as research and it’s unclear whether the Common Rule, which requires informed consent for human subject research, would apply. This lack of clarity leaves newborn data ripe for misuse.
The American Federation of State, County and Municipal Employees (AFSCME), states in support that it provides parents the tools necessary to be fully informed on why and how their child's blood samples are being used by DPH.
OPPOSITION. The California Hospital Association (CHA), California Healthcare Institute, Advanced Medical Technology Association, and Biocom write in opposition to a previous version of the bill that the net result of this bill would be to decrease the number of newborns tested for these devastating disorders which can be prevented or ameliorated if detected. Opponents write that the mothers who are most likely to decline the testing are those without insurance or with high deductibles, and mothers who are inordinately suspicious of government while other mothers might decline testing due to their lack of understanding of science and medicine. CHA further states that this bill would also increase the administrative burdens on hospitals, physicians, and new mothers which, in turn, will increase health care costs. Finally, according to the opposition, this bill bill would increase the legal liability on hospitals and physicians; if a mom opts out of testing her baby, and her baby has one of these devastating disorders which could have been detected, she will likely sue physician and/or hospital.
The University of Southern California states in opposition to a previous version of the bill that the current California bloodspot database serves as an important resource to assist in the early identification of these rare diseases. California's database is internationally recognized as a critical public health asset and allows for the study of these rare diseases among its diverse communities.
The American Academy of Pediatrics, California and March of Dimes California Chapter (March of Dimes) writes in opposition to a previous version of the bill that they oppose any amendments that would link consent for storage and research of newborn screening blood spots with the initial collection and testing of the blood spots. March of Dimes recognizes both the value of newborn screening blood spots for research use by the scientific community and the importance of appropriate parental involvement in decisions regarding storage and use of post-screening blood spots. However, the March of Dimes overriding interest is to safeguard the benefit to newborns of early detection of conditions that seriously threaten their lives or health and the initiation of treatment that is made possible by timely newborn screening.
The California Children's Hospital Association (CCHA) writes with concerns on a previous version of this bill, stating that the current California blood spot database is an internationally recognized public health asset because of its size and diversity. The ability to study rare diseases, diseases contained to small geographical areas or to small subsets of California’s genetically diverse population, as well as the ability to link clinical and environmental data (such as pesticides), would not be possible without California’s blood spot database. Implementing an informed consent policy will require significant financial resources to address education of families, training for health care providers in distributing and explaining the consent forms, logistics and follow-up (e.g. destruction of blood spots). Given that the federal Common Rule must be finalized by the end of 2016 and will then govern these processes for the majority of research in California, it would be best to ensure that state law is congruent with federal policy. Currently, this bill would move ahead with changes to state law that could be in conflict with the final version of the federal regulations.
CCHA concludes that under the legislation as written, parents could receive the consent form twice or more, with the potential for them to change their decision in between. This could lead to confusion at DPH or the hospital gathering the consent forms. This bill should contain some guidance about how to handle this conflict.
CONCERN. The University of California (UC) writes with concerns to a previous version of the bill that this measure could significantly limit the availability of the valuable data and biosamples collected by the CNSP for research use. One of the greatest values of California's current process for collecting and storing newborn dried blood samples comes from its size and diversity. The samples stored by DPH reflect California's diverse population and allows us to research how different diseases affect different ethnicities. The sheer number of samples makes research into rare diseases possible, and also facilitates robust studies of regional environmental factors that can cause disease. This bill's revised process for research use of newborn dried blood samples is likely to severely limit the number of samples that may be collected which in turn, would greatly diminish the research value of the current newborn dried blood samples stored by DPH. The UC indicates concern that the bill's research terminology is inconsistent with the Federal Policy for the Protection of Human Subjects, or the "Common Rule." The Common Rule is utilized by all Human Subject Protection Programs for federally-funded research. The UC worries that the revised consent process under this bill may confuse new parents instead of creating a greater understanding about the benefits of the CNSP and the research it supports.
PREVIOUS LEGISLATION.
AB 1559 (Pan), Chapter 565, Statutes of 2014, expands DPH statewide screening of newborns to include screening for adrenoleukodystrophy (ALD) as soon the federal Recommended Uniform Screening Panel approved the addition of ALD.
SB 222 (Padilla) of 2014 would have enacted the Genetic Information Privacy Act, which would have required an individual’s written authorization prior to the collection of genetic information for testing, analysis, retention, or disclosure. SB 222 was held in the Senate Appropriations Committee.
SB 1267 (Padilla) of 2012 would have required an individual’s written authorization prior to the collection of genetic information for testing, analysis, retention or disclosure. Would have required destruction of the genetic information upon completion of the purpose authorization was obtained. SB 1267 was held in the Senate Appropriations Committee.
AB 395 (Pan), Chapter 461, Statutes of 2011, expands statewide screening of newborns to include screening for severe combined immunodeficiency.
SB 1103 (Committee on Budget and Fiscal Review), Chapter 228, Statutes of 2004, expands statewide screening of newborns to include tandem mass spectrometry screening for fatty acid oxidation, amino acid, organic acid disorders, and congenital adrenal hyperplasia.
SB 537 (Greene), Chapter 1011, Statutes of 1998, required DPH to establish a program to provide extended newborn genetic screening services for persons who elect to have, and pay for, the additional screening.
DOUBLE REFERRAL. This bill has been double referred. It passed the Assembly Committee on Privacy and Consumer Protection with a vote of 9-2 on March 3, 2015
COMMITTEE AMENDMENTS.
Who stores the form? This bill requires the informational acceptance form to be given to a woman at prenatal visits and at the time of delivery. Because of this broad time frame, a child's medical record may not yet exist, and therefore the form would not be able to be stored there as this bill provides. The Committee may recommend amending this bill to provide that the signed informational acceptance form be retained in the mother's medical record.
Default provisions. This bill does not indicate what happens in the event that there is no signed informational acceptance form. Because care providers are now required to retain a signature on documents, it could lead to confusion on what happens when a form is not present. The Committee may recommend amending this bill to make it clear that in the event that there is not a signed informational acceptance form on file, the care provider is directed to submit the NBS sample for storage and research.
Technical/clarifying amendments.
Regarding the process for parents to opt-out of a newborn screening test if they wish to do so, current statute reads as follows:
"(d) This section shall not apply if a parent or guardian of the newborn child objects to a test on the ground that the test conflicts with his or her religious beliefs or practices."
Amendments submitted by the author sought to keep the language
regarding the process for the NBS test exactly the same. Some
changes were inadvertently made during the drafting process, and the
Committee may recommend amendments that will reinstate this language
and maintain exactly what is currently in statute regarding the
newborn genetic disease screening test process.
Section 2 (c) of this bill requires DPH to provide to a parent or legal guardian a standard informational acceptance form regarding the options for newborn child screening and retention of newborn child blood samples collected. The informational acceptance form is intended to apply only to the storage of child blood samples that are collected, and is not intended to be a part of the newborn screening test procedures. The Committee may recommend clarifying and conforming amendment language as follows:
Page 6, line 36-37: "(c) The department shall provide to a
parent or legal guardian the standard informational acceptance form
provided in Section 125004 regarding the options for
newborn child screening and retention of newborn
child blood samples collected pursuant to this article."
Page 8, line 11 – "(4) A space for the parent or legal
guardian of the newborn child to acknowledge receipt of informational
materials regarding the newborn child screening test,
and the storage, retention, and use of the newborn
child’s blood sample for medical research."
REGISTERED SUPPORT / OPPOSITION:
Support
American Federation of State, County and Municipal Employees
Council
for Responsible Genetics
Opposition
Advanced Medical Technology Association (prior version)
American
Academy of Pediatrics, California (prior version)
Biocom (prior
version)
California Children's Hospital Association (prior
version)
California Healthcare Institute (prior
version)
California Hospital Association
March of Dimes
California Chapter
University of Southern California (prior
version)
Analysis Prepared by: Paula Villescaz / HEALTH / (916) 319-2097
AB 170
Page 6
Date of Hearing: April 14, 2015
ASSEMBLY COMMITTEE ON HEALTH
Rob Bonta, Chair
AB 170
(Gatto) – As Amended March 25, 2015
SUBJECT: Newborn screening: genetic diseases: blood samples collected
SUMMARY: Prohibits the Department of Public Health (DPH) from testing a newborn child and retaining a blood sample for medical research unless the parent or guardian provides informed consent, as specified. Specifically, this bill:
Prohibits DPH from testing a newborn child unless the parent or guardian provides informed consent, as specified.
Prohibits DPH from storing, retaining, or using for medical research a blood sample collected unless the parent or guardian provides informed consent, as specified.
Authorizes a parent or guardian of a minor child and the newborn child, once he or she is at least 18 years of age, to request that DPH destroy or not use for research purposes, or both, the blood sample.
Requires DPH to destroy blood samples if an individual that has reached at least 18 years of age, or a parent or guardian of a minor child, requests DPH to do so.
Requires DPH to prepare and provide informational materials regarding the newborn child blood samples collected that includes, but is not limited to, information on storage, retention, and use of the blood sample, and the right of specified persons to request that the blood sample be destroyed or not used for research purposes, or both.
Requires DPH to prepare and provide a standard informed consent form, to be distributed as specified, that includes an explanation of the newborn child screening test and a space for the parent or legal guardian of the newborn child to indicate his or her consent to the storage, retention, and use of the blood sample for medical research.
EXISTING LAW:
Requires DPH to establish a genetic disease unit to coordinate all DPH programs in the area of genetic disease that will promote a statewide program of information, testing, and counseling services and to have the responsibility of designating tests and regulations to be used in executing this program and to have the responsibility of designating tests and regulations to be used in executing the California Newborn Screening Program (CNSP).
Requires DPH to provide genetic screening and follow-up services. Allows DPH to provide laboratory (lab) testing facilities or work with qualified outside labs to conduct testing.
Requires DPH to charge a fee for newborn screening and follow-up services, and requires the amount of the fee to be periodically adjusted in order to meet the costs of CNSP.
Requires DPH to evaluate and prepare recommendations on the implementation of tests for the detection of hereditary and congenital diseases, including, but not limited to, biotinidase deficiency and cystic fibrosis. Requires DPH to also evaluate and prepare recommendations on the availability and effectiveness of preventative follow-up interventions, including the use of specialized medically necessary dietary products.
Requires statewide screening of newborns to include tandem mass spectrometry screening for fatty acid oxidation, amino acid, and organic acid disorders and congenital adrenal hyperplasia. Also requires screening of newborns to include screening for severe combined immunodeficiency, as soon as possible.
FISCAL EFFECT: This bill has not yet been analyzed by a fiscal committee.
COMMENTS:
PURPOSE OF THIS BILL. According to the author, newborn screening is one of the great public health success stories in this country, but what happens to the samples after the screening process is completed raises serious and troubling questions of consent and privacy. In the case of California and a handful of other states, these samples are indefinitely stored in state repositories and made available to researchers for a fee. The author states that most parents are poorly informed, if at all, about the storage and medical research of these samples.
The author argues that parents are assumed to have consented to long-term storage and third-party use of their child's biological sample unless they explicitly refuse in writing. California must revise its approach to long-term storage and use of newborn DNA samples, and include parents in the decision-making process. It is imperative for both the health of this program and Californians' continued trust in their government that parents be fully informed of the Biobank program and the intended future use of their child's DNA.
The author concludes that this bill will ensure that parents have the right to protect their children's genetic privacy. Parents, understandably, want to be actively involved in decision-making regarding their children's personal health information. That choice is currently being denied.
BACKGROUND. In 1966 California began its CNSP with the testing of phenylketonuria. Since its creation, the CNSP has been expanded several times as new discoveries are made and tests developed and now screens for more than 70 disorders. Diseases have been added through regulation and legislation.
CNSP. Prior to leaving the hospital, a few drops of blood from the newborn’s heel are collected on filter paper. The newborn screening test should be done when the baby is at least 12 hours of age but before six days of age. The ideal time to do the test is when the baby is between 24 and 48 hours of age. Blood collected before 12 hours of age is not always reliable for some metabolic diseases. The sample is sent to one of eight regional labs that contract with the DPH for testing. The results are sent to DPH for data collection and quality control. Parents obtain the test results from the baby’s doctor or clinic. It takes about two weeks for the doctor to receive the written results. If the baby needs more tests, parents get a letter or a phone call a few days after discharge from the hospital. Positive test results are immediately telephoned to a follow-up coordinator at one of the Newborn Screening Area Service Centers throughout the State. The coordinator contacts the newborn’s physician to arrange for repeat testing. If repeat testing determines that the baby has a disorder, the coordinator will supply the latest clinical information on diagnosis and treatment and assist with referrals to special care. In 2009-10, approximately 520,000 newborns were screened for 75 genetic disorders. Approximately 9,200 or under 2% were classified as positive or questionable and were referred for follow-up testing or services.
Disorders screened for by the CNSP have varying degrees of severity. If identified early many of these conditions can be treated before they cause serious health problems. Treatments may include medication, dietary supplements, avoidance of fasting and/or special diet and comprehensive care to reduce morbidity and mortality. This test screens for specific diseases in the following groups:
Metabolic: chemical reactions in the body to create energy and build tissue;
Endocrine: hormones that affect body functions;
Hemoglobin: red blood cells that carry oxygen;
Other Genetic Diseases;
Cystic Fibrosis; and,
Severe Combined Immunodeficiency.
CNSP disorders cause delays in development, neurological damage,
dehydration, incorrect sex assignment, mental retardation, and death
if not treated at an early newborn age. In California about one out
of every 600 babies tested will have one of these diseases.
Current regulations permit a parent to decline the test. A parent
must then sign a special form that states that not having the test
done can result in serious illness or permanent damage to their
child. It also states that the parent must accept responsibility
should this occur.
California BioBank. DPH maintains a large and diverse biobank, the California Biobank Program, which houses over 17.5 million prenatal serum samples and newborn leftover blood spots. These samples were collected for testing by the Prenatal and Screening Program and CNSP that are administered by the Genetic Disease Screening Program (GDSP) and are linked to GDSP data and California Birth Defects Monitoring Program (CBDMP) registry data. The samples and data are also linked to the State Registrar of Vital Statistics databases that include fetal death, live birth and death data. The California Biobank Program (CBP) is an internationally recognized public health asset because of its large size and culturally, geographically and genetically diverse population. The CBP is unique in that no other state or international effort approaches its scale in terms of the number and quality of specimens collected and preserved annually, the number of historic specimens, and existing linkage with statewide prenatal and newborn screening program data, birth defects data, CBDMP data and other population databases.
OPPOSITION. The California Hospital Association (CHA), California Healthcare Institute, Advanced Medical Technology Association, and Biocom write in opposition to the bill that the net result of this bill would be to decrease the number of newborns tested for these devastating disorders which can be prevented or ameliorated if detected. Opponents write that the mothers who are most likely to decline the testing are those without insurance or with high deductibles, and mothers who are inordinately suspicious of government while other mothers might decline testing due to their lack of understanding of science and medicine. CHA further states that this bill would also increase the administrative burdens on hospitals, physicians, and new mothers which, in turn, will increase health care costs. Finally, according to the opposition, this bill bill would increase the legal liability on hospitals and physicians; if a mom opts out of testing her baby, and her baby has one of these devastating disorders which could have been detected, she will likely sue physician and/or hospital.
The University of Southern California states in opposition that the current California blood spot database serves as an important resource to assist in the early identification of these rare diseases. California's database is internationally recognized as a critical public health asset and allows for the study of these rare diseases among its diverse communities.
The American Academy of Pediatrics, California and March of Dimes California Chapter (March of Dimes) writes in opposition that they oppose any amendments that would link consent for storage and research of newborn screening blood spots with the initial collection and testing of the blood spots. March of Dimes recognizes both the value of newborn screening blood spots for research use by the scientific community and the importance of appropriate parental involvement in decisions regarding storage and use of post-screening blood spots. However, the March of Dimes overriding interest is to safeguard the benefit to newborns of early detection of conditions that seriously threaten their lives or health and the initiation of treatment that is made possible by timely newborn screening.
The California Children's Hospital Association (CCHA) writes with concerns about this bill, stating that the current California blood spot database is an internationally recognized public health asset because of its size and diversity. The ability to study rare diseases, diseases contained to small geographical areas or to small subsets of California’s genetically diverse population, as well as the ability to link clinical and environmental data (such as pesticides), would not be possible without California’s blood spot database. Implementing an informed consent policy will require significant financial resources to address education of families, training for health care providers in distributing and explaining the consent forms, logistics and follow-up (e.g. destruction of blood spots). Given that the federal Common Rule must be finalized by the end of 2016 and will then govern these processes for the majority of research in California, it would be best to ensure that state law is congruent with federal policy. Currently, this bill would move ahead with changes to state law that could be in conflict with the final version of the federal regulations.
CCHA concludes that under the legislation as written, parents could receive the consent form twice or more, with the potential for them to change their decision in between. This could lead to confusion at CDPH or the hospital gathering the consent forms. This bill should contain some guidance about how to handle this conflict.
CONCERN. The University of California (UC) writes with concerns that this measure could significantly limit the availability of the valuable data and biosamples collected by the CNSP for research use. One of the greatest values of California's current process for collecting and storing newborn dried blood samples comes from its size and diversity. The samples stored by DPH reflect California's diverse population and allows us to research how different diseases affect different ethnicities. The sheer number of samples makes research into rare diseases possible, and also facilitates robust studies of regional environmental factors that can cause disease. This bill's revised process for research use of newborn dried blood samples is likely to severely limit the number of samples that may be collected which in turn, would greatly diminish the research value of the current newborn dried blood samples stored by DPH. The UC indicates concern that the bill's research terminology is inconsistent with the Federal Policy for the Protection of Human Subjects, or the "Common Rule." The common rule is utilized by all Human Subject Protection Programs for federally-funded research. The UC worries that the revised consent process under this bill may confuse new parents instead of creating a greater understanding about the benefits of the NSP and the research it supports.
PREVIOUS LEGISLATION.
AB 1559 (Pan), Chapter 565, Statutes of 2014, expands DPH statewide screening of newborns to include screening for adrenoleukodystrophy (ALD) as soon the federal Recommended Uniform Screening Panel approved the addition of ALD.
SB 222 (Padilla) of 2014 would have enacted the Genetic Information Privacy Act, which would have required an individual’s written authorization prior to the collection of genetic information for testing, analysis, retention or disclosure. SB 222 was held in the Senate Appropriations Committee.
SB 1267 (Padilla) of 2012 would have required an individual’s written authorization prior to the collection of genetic information for testing, analysis, retention or disclosure. The bill would have required destruction of the genetic information upon completion of the purpose authorization was obtained. SB 1267 was held in the Senate Appropriations Committee.
SB 1731 (Block), Chapter 336, Statutes of 2012, established the Newborn Critical Congenital Heart Disease (CCHD) Screening Program and required hospitals, beginning July 1, 2013, to offer a pulse oximetry test for the identification of CCHD to parents of newborns prior to discharge.
AB 395 (Pan), Chapter 461, Statutes of 2011, expands statewide screening of newborns to include screening for severe combined immunodeficiency.
SB 1103 (Committee on Budget and Fiscal Review), Chapter 228, Statutes of 2004, expands statewide screening of newborns to include tandem mass spectrometry screening for fatty acid oxidation, amino acid, organic acid disorders, and congenital adrenal hyperplasia.
AB 442 (Committee on Budget), Chapter 1161, Statutes of 2002, requires hospitals to collect fees associated with any tests conducted under CNSP.
SB 537 (Greene), Chapter 1011, Statutes of 1998, required DPH to establish a program to provide extended newborn genetic screening services for persons who elect to have, and pay for, the additional screening.
COMMITTEE AMENDMENTS. The CNSP program is crucial to protecting each newborn from identifiable and preventable diseases. Approximately 10,000 newborn screenings per year are classified as positive or questionable and are referred for follow-up testing or services. Potentially saving the lives of 10,000 babies outweighs any privacy protections that parents may lay claim to. For this reason, the Committee suggests amendments that remove any opt-in requirements to have a newborn screened at birth.
On page 3, strike lines 29-34, and replace it with:
(d) This
section shall not apply if a parent or guardian of the newborn child
objects to a test.
The Committee is sympathetic towards the many concerns raised by the opposition and scientific community regarding opt-in requirements to have dried blood spot samples stored and used for research. Because the potential impacts on research are uncertain, the Committee may wish to make an amendment that would sunset these provisions of this bill.
On page 5, line 19 add:
(k) Section 125000 (d) (2) shall be repealed on January 1, 2022.
On page 7, line 32 add:
(e) Section 125004 (a) (4) and (6) (b) shall be repealed on January 1, 2022.
REGISTERED SUPPORT / OPPOSITION:
Support
American Federation of State, County and Municipal Employees
Opposition
Advanced Medical Technology Association
American Academy of
Pediatrics, California
Biocom
California Children's
Hospital Association
California Healthcare Institute
California
Hospital Association
March of Dimes California
Chapter
University of Southern California
Analysis Prepared by: Paula Villescaz / HEALTH / (916) 319-2097
AB 170
Page 7
Date of Hearing: March 17, 2015
ASSEMBLY COMMITTEE ON PRIVACY AND CONSUMER PROTECTION
Gatto, Chair
AB 170
(Gatto) – As Amended March 11, 2015 As Proposed to be Amended
SUBJECT:
Newborn screening: genetic diseases: blood samples collected
SUMMARY:
Requires the Department of Public Health (DPH) to prepare and provide informational materials about the California Newborn Screening Program (CNSP) to a parent or guardian of a newborn prior to a newborn screening test, and requires DPH to obtain written informed consent from a parent or legal guardian before storing, retaining and using a newborn’s blood sample for medical research. Specifically, this bill:
Requires DPH to:
Obtain the informed consent of the parent or guardian of a newborn child before storing, retaining or using a newborn child’s blood sample for medical research and defines “informed consent” for purposes of the CNSP as “a written authorization signed and dated by a parent or legal guardian of a newborn child”;
Destroy, or not use for research purposes, the blood sample of a minor, upon request of the minor’s parent or legal guardian;
Destroy, or not use for research purposes, the blood sample of an individual who is at least 18 years of age, upon request of the individual;
Prepare and provide informational materials on the CNSP that explain to parents and guardians of newborn children the following:
The storage, retention and use of the blood sample;
The parent or guardian’s right to request that a blood sample be destroyed or not used for research purposes; and
The right of an individual at least 18 years of age to request that his or her blood sample be destroyed or not used for research purposes.
Prepare and provide a standard informed consent form for the CNSP that sets forth clearly and in detail the following:
The purpose of the newborn child screening test and retention of newborn blood samples;
The benefits of the screening and the research undertaken regarding heritable and congenital disorders;
A space for the parent or legal guardian to acknowledge receipt of informational materials about the newborn child screening test;
A space for the parent or legal guardian to indicate his or her consent to the storage, retention, and use of the newborn’s blood sample for medical research;
A space for the parent to legal guardian to indicate his or her request for information about the right to refuse a newborn child screening test on the ground that the test conflicts with his or her religious beliefs or practices; and
A space for the parent or legal guardian to sign and date the form.
Requires that a parent or guardian of a newborn child must receive the CNSP informational materials and informed consent form prior to the newborn screening test.
Requires every birth attendant engaged in perinatal care to provide the DPH informational materials and standard informed consent form to a pregnant woman.
Requires every perinatal licensed health facility to provide the DPH informational materials and standard informed consent form to each pregnant woman admitted for delivery prior to the collection of the blood sample, if the consent form was not already provided during perinatal care.
Requires every local registrar of births to provide the DPH informational materials and standard informed consent form to each person registering the birth of a newborn that occurred outside of a perinatal licensed health facility when the newborn was not admitted to a perinatal licensed health facility within the first 30 days of age.
Requires a copy of the standard informed consent form to be maintained with the newborn child’s medical records.
Specifies that DPH may not store, retain, or use for medical research a newborn child’s blood sample collected and used for the newborn screening test, unless the parent or guardian of the newborn child indicates his or her consent on a completed informed consent form.
Makes other clarifying or nonsubstantive changes.
EXISTING LAW:
Requires DPH to establish a genetic disease unit to coordinate all DPH programs in the area of genetic disease that promotes a statewide program of information, testing, and counseling services, designates tests and regulations to be used in executing this program, and designates tests and regulations used in executing the CNSP. (Health and Safety Code (HSC) Section 124977 et seq.)
Requires DPH to fully inform a parent or guardian of a minor of the purposes of testing for hereditary disorders prior to performing any genetic testing. (HSC 124980)
Specifies that no test may be performed on any minor over the objection of the minor’s parent or guardian and requires DPH to give a parent or guardian of a minor a reasonable opportunity to object. (HSC 124980)
Gives the parent or guardian of the newborn child a specific option to object to the newborn screening test on the ground that the test conflicts with his or her religious beliefs or practices. (HSC 125000)
Requires DPH to provide genetic screening and follow-up services, allows DPH to provide laboratory testing facilities or work with qualified outside labs to conduct testing, requires DPH to charge a fee for newborn screening and follow-up services, and requires the amount of the fee to be periodically adjusted in order to meet the costs of CNSP. (HSC 124977 and 125000)
Prohibits, under the State Confidentiality of Medical Information Act (CMIA), providers of health care, health care service plans, or contractors, as defined, from sharing medical information without the patient’s written authorization, subject to exceptions, including among others, certain research. (Civil (Civ.) Code Section 56 et seq.)
Protects, under the federal Health Insurance Portability and Accountability Act (HIPAA), the privacy of patients’ health information and generally provides that a covered entity, as defined (health plan, health care provider, and health care clearing house), may not use or disclose “protected,” i.e., individually identifiable, health information except as specified or as authorized by the patient in writing. (45 Code of Federal Regulations Section 160 et seq.)
Prohibits, under the Unruh Civil Rights Act and the Fair Employment and Housing Act (FEHA), discrimination on the basis of genetic information. (Civ. Code 51 and Government Code Section 12920 et seq.)
Prohibits, under the federal Genetic Information and Nondiscrimination Act (GINA), discrimination in group health plan coverage and employment based on genetic information. (Public Law 110-233)
Requires separate written consent for the release of certain types of sensitive medical information, including: HIV status and test results, the donation of human egg cells for research purposes, and genetic test results for life or disability insurance applications. (HSC 120975-121125; HSC 125350 et seq.; and Insurance Code (IC) Section 10140.1)
Establishes various penalties concerning the disclosure of genetic test results, when the genetic test is requested by an insurer for purposes of life or disability insurance. (IC 10149.1)
FISCAL EFFECT:
Unknown
COMMENTS:
Purpose of this bill. This bill is intended to ensure that parents receive information about the CNSP and protect children’s genetic privacy by requiring DPH to obtain written informed consent from parents and guardians before keeping and using children’s genetic data for medical research. This measure will be heard as proposed to be amended, based upon mocked-up amendments provided by the author. This measure is author-sponsored.
Author’s statement. According to the author's office, “AB 170 is necessary because, regardless of current regulations, the majority of parents are not aware that their child’s newborn blood sample is being retained by the state and may potentially be used in research. A report from the Council for Responsible Genetics cites numerous studies that indicate the vast majority of surveyed parents would prefer an informed consent process instead of the current opt-out afforded to them. Most interestingly, a study by Beth Tarini found that “[i]f parental permission was obtained, most parents reported that they would either be ‘very willing’(38%) or ‘somewhat willing’ (37.4%) to permit use of their children’s newborn screening samples for future research studies . . . If parental permission was not obtained, substantially fewer parents reported that they would either be ‘very willing’ (11.3%) or ‘somewhat willing’ (16.9%) to permit use of the [CNSP] sample for research. Moreover, over half of parents (55.7%) would be ‘very unwilling’ to permit the use of their child’s newborn screening sample for research purposes.”
CNSP. According to DPH, the CNSP is recognized nationally as an essential preventive health program. All states in the nation and the District of Columbia have established newborn screening programs. In California, the test is administered to virtually every newborn before the baby leaves the hospital by taking a few drops of blood from the baby’s heel and placing the blood spots on a special filter paper that is then sent to a state-approved laboratory for testing.
If identified early, many genetic disorders can be treated before they cause serious health problems. According to DPH, approximately 500,000 newborns are screened each year for over 80 genetic and congenital disorders, and about 875 children are identified with a genetic disorder each year in California. Parents can get the test results from the baby's doctor or clinic, which takes about two weeks. If the baby needs more tests, parents will get a letter or a phone call a few days after discharge from the hospital. Positive test results are immediately telephoned to a follow-up coordinator at one of the Newborn Screening Area Service Centers throughout the state. The coordinator contacts the newborn's physician to arrange for repeat testing. If repeat testing determines that the baby has a disorder, the coordinator will supply the latest clinical information on diagnosis and treatment and assist with referrals to special care clinics. Medi-Cal, health plans, and most private insurance providers pay for the test.
The California Biobank. According to DPH, blood samples collected from newborns under the CNSP are maintained in the California Biobank which contains the combined biospecimen and data resources of two DPH screening and monitoring programs, the California Genetic Disease Screening Program (GDSP) and the California Birth Defects Monitoring Program. GDSP administers the CNSP and the Prenatal Screening Program. The California Biobank is required to makes specimens and related data available to researchers for the following approved purposes:
Identify risk factors for children’s and women’s diseases;
Develop and evaluate screening tests;
Develop and evaluate screening strategies; and,
Develop and evaluate treatments.
The California Biobank houses more than 16 million newborn blood samples. According to DPH, since the CNSP began in 1980, the GDSP has banked leftover blood spots from screened newborns in freezer storage, but only those banked since 1982 are readily available. The specimens are physically labeled with a unique number and stored without any identifying information. Researchers may receive both specimens and the data related to specimens. GDSP’s 16 million newborn specimens represent “an entire generation of Californians” according to DPH.
Current privacy and consumer protections for genetic data. Currently, federal and state laws offer various protections for genetic information. For example, HIPAA and CMIA generally require a patient’s written consent before disclosure of medical information. In 2008, the federal government enacted GINA to prohibit discrimination in group health plan coverage and employment based on genetic information. In California, the Unruh Civil Rights Act and FEHA prohibit discrimination on the basis of genetic information.
Current law governing the CNSP requires DPH to fully inform a parent
or guardian of the purposes of the newborn screening test and offer a
reasonable opportunity to opt-out of the test for religious
reasons.
This bill would expand the current privacy
protections in place for CNSP by creating an opt-in consent
requirement – not for the test itself – but for the future
storage, retention and use of a newborn’s blood sample for medical
research. In addition to requiring opt-in consent for medical
research uses, the bill also strengthens current privacy law by
specifically requiring informational materials about the CNSP program
to be provided prior to newborn testing, and by requiring DPH
to create and use a standard informed consent form that contains
spaces for a parent or guardian to:
Acknowledge receipt of informational materials;
Opt in to medical research uses of the blood sample taken; and,
Request more information about opting out of the newborn screening test itself.
Privacy and genetic data. As noted by the United States Department of Health and Human Services (DHHS) in a 2009 progress report, genetic information raises unique ethical and legal issues that other types of medical information may not. According to that report: “A particular concern is that whole-genome scans will provide a unique DNA identifier that could potentially be linked with data obtained or stored in other contexts, which has implications for consent and privacy.” (A Progress Report and Future Directions of the Secretary’s Advisory Committee on Genetics, Health, and Society, The Integration of Genetic Technologies Into Health Care and Public Health, January 2009, p. 8.)
While the benefits of having large databanks of genetic data for medical research are undisputed, the author contends that the unknown potential future uses of genetic data create the need for revisiting current law privacy protections for genetic data. In fact, in October 2012, the Presidential Commission for the Study of Bioethical Issues, an advisory panel of the nation’s leaders in medicine, science, ethics, religion, law, and engineering, released a report that recommends adopting new policies to help ensure privacy and security as the field of genomics advances and urged federal and state governments to ensure a consistent floor of privacy protections covering whole genome sequencing data regardless of how that genetic information was obtained. (Privacy and Progress in Whole Genome Sequencing, Presidential Commission for the Study of Bioethical Issues, Oct. 11, 2012)
By way of precedent, California law already requires a separate written consent for other types of sensitive medical information, including:
Genetic test results for a life or disability insurance application;
HIV status and test results, except for diagnosis, care, and treatment; and,
Donation of human egg cells for research purposes.
Arguments in support. The American Federation of State, County and Municipal Employees (AFSCME) states in support of the bill, “AFSCME supports AB 170 because we believe that a person must have the right to decide how their blood samples are being used.”
Arguments in opposition. According to the California Hospital Association, “This bill changes the current system of testing newborns for preventable heritable and congenital disorders which has worked very well in California for over 30 years. Currently, hospitals provide new mothers with written information developed by the California Department of Public Health about newborn testing. Mothers then have the ability to decline the testing if they wish. Very few mothers decline testing their babies for these disorders. The net result of this bill would be to decrease the number of newborns tested for these devastating disorders which can be prevented or ameliorated if detected.”
Prior Legislation. AB 1559 (Pan), Chapter 565, Statutes of 2014, expanded DPH statewide screening of newborns to include screening for adrenoleukodystrophy (ALD) as soon the federal Recommended Uniform Screening Panel approved the addition of ALD.
SB 222 (Padilla) of 2014 would have enacted the Genetic Information Privacy Act, which would have required an individual’s written authorization prior to the collection of genetic information for testing, analysis, retention or disclosure. SB 222 was held in the Senate Appropriations Committee.
SB 1267 (Padilla) of 2012 would have required an individual’s
written authorization prior to the collection of genetic information
for testing, analysis, retention or disclosure. The bill would have
required destruction of the genetic information upon completion of
the purpose authorization was obtained. SB 1267 was held in the
Senate Appropriations Committee.
SB 1731 (Block),
Chapter 336, Statutes of 2012, established the Newborn Critical
Congenital Heart Disease (CCHD) Screening Program and required
hospitals, beginning July 1, 2013, to offer a pulse oximetry test for
the identification of CCHD to parents of newborns prior to
discharge.
AB 395 (Pan), Chapter 461, Statutes of 2011,
expanded statewide screening of newborns to include screening for
severe combined immunodeficiency.
SB 1103 (Committee on
Budget and Fiscal Review), Chapter 228, Statutes of 2004, expanded
statewide screening of newborns to include tandem mass spectrometry
screening for fatty acid oxidation, amino acid, organic acid
disorders, and congenital adrenal hyperplasia.
AB 442
(Committee on Budget), Chapter 1161, Statutes of 2002, required
hospitals to collect fees associated with any tests conducted under
CNSP.
SB 537 (Greene), Chapter 1011, Statutes of 1998,
required DPH to establish a program to provide extended newborn
genetic screening services for persons who elect to have, and pay
for, the additional screening.
Double-referral. This bill has been double-referred to the Assembly Health Committee, where it will be heard if passed by this Committee.
REGISTERED SUPPORT / OPPOSITION:
Support
American Federation of State, County and Municipal Employees (AFSCME)
Opposition (Prior Version)
California Hospital Association (CHA)
Analysis Prepared by:
Jennie Bretschneider/P. & C.P./(916) 319-2200
Discussed in Hearing
Senate Standing Committee on Health
Assembly Floor
Assembly Standing Committee on Health
Assembly Standing Committee on Health
Bill Author
Bill Co-Author(s):